3,679 results on '"The Walter and Eliza Hall Institute of Medical Research"'
Search Results
2. A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma (AB-218-IIT-201)
- Author
-
Walter and Eliza Hall Institute of Medical Research and AnHeart Therapeutics Inc.
- Published
- 2024
3. Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART (AMBER)
- Author
-
The Peter Doherty Institute for Infection and Immunity, Walter and Eliza Hall Institute of Medical Research, The Alfred, and Aarhus University Hospital
- Published
- 2024
4. RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer (RESOLUTE)
- Author
-
Walter and Eliza Hall Institute of Medical Research and Cancer Council Victoria
- Published
- 2023
5. Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient (CReSCT)
- Author
-
Peter MacCallum Cancer Centre, Australia, Western Sydney Local Health District, Walter and Eliza Hall Institute of Medical Research, Austin Hospital, Melbourne Australia, and Monica Slavin, Infectious Diseases Physician
- Published
- 2023
6. Serological Screen and Treat Trial for Plasmodium Vivax (SSAT)
- Author
-
Eijkman Institute for Molecular Biology, Eijkman Oxford Clinical Research Unit, Indonesia, Walter and Eliza Hall Institute of Medical Research, Rumah Sakit Umum Daerah Mimika, Universitas Sumatera Utara, and Inge Sutanto, Professor
- Published
- 2023
7. Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns (ECG-Lihir)
- Author
-
Walter and Eliza Hall Institute of Medical Research, Papua New Guinea Institute of Medical Research, Barcelona Institute for Global Health, and Oriol Mitja, Assistant Professor
- Published
- 2016
8. Inoculating Celiac Disease Patients With the Human Hookworm Necator Americanus: Evaluating Immunity and Gluten-sensitivity
- Author
-
The Broad Foundation, Townsville Hospital, James Cook University, Queensland, Australia, Walter and Eliza Hall Institute of Medical Research, Queensland Institute of Medical Research, and A James M Daveson, Doctor
- Published
- 2016
9. Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection
- Author
-
Walter and Eliza Hall Institute of Medical Research, The University of Western Australia, University of Oxford, and Curtin University
- Published
- 2015
10. Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity
- Author
-
Walter and Eliza Hall Institute of Medical Research, Swiss Tropical & Public Health Institute, and Barcelona Centre for International Health Research
- Published
- 2014
11. Surveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine
- Author
-
Walter and Eliza Hall Institute of Medical Research and Inge Sutanto, Prof. DR. dr.
- Published
- 2014
12. Safety and Efficacy of Primaquine for P. Vivax
- Author
-
Walter and Eliza Hall Institute of Medical Research, Ministry of Health, Vanuatu, Ministry of Health, Solomon Islands, and World Health Organization
- Published
- 2013
13. Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea (IPTp in PNG)
- Author
-
Papua New Guinea Institute of Medical Research, The University of Western Australia, Walter and Eliza Hall Institute of Medical Research, University of Barcelona, and Stephen Rogerson, Professor of Medicine
- Published
- 2013
14. Human Thyroid-Stimulating Hormone: Structure–Function Analysis
- Author
-
Szkudlinski, Mariusz W., Grossmann, Mathis, Leitolf, Holger, and Weintraub, Bruce D.
- Published
- 2000
- Full Text
- View/download PDF
15. Segregating Sites in a Gene Conversion Model with Mutation
- Author
-
Bahlo, Melanie
- Published
- 1998
- Full Text
- View/download PDF
16. Iscoms Containing PurifiedQuillajaSaponins Upregulate both Th1-like and Th2-like Immune Responses
- Author
-
Sjölander, Anders, van 't Land, Belinda, and Bengtsson, Karin Lövgren
- Published
- 1997
- Full Text
- View/download PDF
17. Natural killers or ILC1s? That is the question
- Author
-
Eric Vivier, Laurent Brossay, Cyril Seillet, Olivia Newton-John Cancer Research Institute, La Trobe University School of Cancer Medicine, Heidelberg, VIC 3084, Australia, The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology, University of Melbourne, Melbourne, VIC 3052, Australia., The Walter and Eliza Hall Institute of Medical Research (WEHI), Innate Pharma, Centre d'Immunologie de Marseille - Luminy (CIML), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)
- Subjects
0301 basic medicine ,Tumor immunosurveillance ,[SDV]Life Sciences [q-bio] ,Immunology ,Innate lymphoid cell ,Biology ,Phenotype ,Lymphocyte Subsets ,Article ,Cell biology ,Killer Cells, Natural ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Transcriptional regulation ,Immunology and Allergy ,Animals ,Humans ,ComputingMilieux_MISCELLANEOUS ,030215 immunology - Abstract
Group 1 innate lymphoid cells (ILCs) comprise the natural killer (NK) cells and ILC1s. Both cells co-exist in peripheral tissues and despite effort to characterise the molecular identity and developmental pathways of ILC1s however their relationship with NK cells remains elusive. ILC1s and NK cells share many common features and analysis of ILC1s in tissues revealed a great heterogeneity and distinct transcriptional requirement of each ILC1 subsets complexifying the organisation of this group. Here, we discuss whether ILC1 and NK cells can be considered as distinct lineages based on their origin, location, phenotype or transcriptional regulation. Discrimination of NK cells and ILC1s represent an important challenge to unravel the individual functions of these cells during infection and tumour immunosurveillance.
- Published
- 2020
- Full Text
- View/download PDF
18. Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network
- Author
-
Guillermina Lozano, Terence P. Speed, Alan Herschtal, Thierry Soussi, Han Liang, Ygal Haupt, Sue Haupt, Franco Caramia, Hu Chen, University of Melbourne, Karolinska Institutet [Stockholm], Cancer Center Karolinska [Karolinska Institutet] (CCK), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), The University of Texas Medical School at Houston, MD Anderson Cancer Center [Houston], The University of Texas Health Science Center at Houston (UTHealth), Baylor College of Medicine (BCM), Baylor University, The University of Texas M.D. Anderson Cancer Center [Houston], The Walter and Eliza Hall Institute for Medical Research (WEHI), Monash University [Melbourne], École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), and The Walter and Eliza Hall Institute of Medical Research (WEHI)
- Subjects
0301 basic medicine ,Male ,Mutation rate ,General Physics and Astronomy ,medicine.disease_cause ,law.invention ,0302 clinical medicine ,Mutation Rate ,law ,Genes, X-Linked ,Neoplasms ,Exome ,Protein Interaction Maps ,lcsh:Science ,Tumour-suppressor proteins ,Cancer genetics ,X chromosome ,Genetics ,Regulation of gene expression ,Mutation ,Multidisciplinary ,[SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM] ,3. Good health ,Gene Expression Regulation, Neoplastic ,030220 oncology & carcinogenesis ,Female ,Science ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Biology ,General Biochemistry, Genetics and Molecular Biology ,Article ,03 medical and health sciences ,Sex Factors ,medicine ,Humans ,Gene ,Chromosomes, Human, X ,Cancer ,General Chemistry ,medicine.disease ,United States ,Computational biology and bioinformatics ,030104 developmental biology ,[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics ,Suppressor ,lcsh:Q ,Tumor Suppressor Protein p53 ,SEER Program - Abstract
The disproportionately high prevalence of male cancer is poorly understood. We tested for sex-disparity in the functional integrity of the major tumor suppressor p53 in sporadic cancers. Our bioinformatics analyses expose three novel levels of p53 impact on sex-disparity in 12 non-reproductive cancer types. First, TP53 mutation is more frequent in these cancers among US males than females, with poorest survival correlating with its mutation. Second, numerous X-linked genes are associated with p53, including vital genomic regulators. Males are at unique risk from alterations of their single copies of these genes. High expression of X-linked negative regulators of p53 in wild-type TP53 cancers corresponds with reduced survival. Third, females exhibit an exceptional incidence of non-expressed mutations among p53-associated X-linked genes. Our data indicate that poor survival in males is contributed by high frequencies of TP53 mutations and an inability to shield against deregulated X-linked genes that engage in p53 networks., There is disproportionally high cancer prevalence in males. Here, the authors analyse the tumour suppressor p53 in sporadic cancers, highlighting a higher incidence of its mutation in males. Males are further disadvantaged by a failure to shield against the expression of damaged X-linked genes in p53-networks. These factors likely contribute to sex-disparity.
- Published
- 2018
- Full Text
- View/download PDF
19. Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis
- Author
-
Kloprogge, F, Workman, Borrmann, Tékété, Lefèvre, Hamed, Piola, Ursing, Kofoed, Mårtensson, Ngasala, Björkman, Ashton, Hietala, Aweeka, Parikh, Mwai, Davis, Karunajeewa, Salman, Checchi, Fogg, Newton, PN, Mayxay, M, Deloron, Faucher, Nosten, F, Ashley, E, McGready, R, Vugt, v, Proux, S, Price, R, Karbwang, Ezzet, Bakshi, Stepniewska, K, White, N, Guerin, P, Barnes, Tarning, J, Institute for Global Health, Imperial College London, Institute for Tropical Medicine [Tübingen, Germany], University of Tübingen [Germany], Département d'Epidémiologie des Affections parasitaires, Malaria Research and training center Université de Bamako, Mali, Université de Bamako, Institut Pasteur du Cambodge, Réseau International des Instituts Pasteur (RIIP), Department of Microbiology, Tumour and Cell biology [Stockholm, Sweden] (Malaria Research), Karolinska Institutet [Stockholm], Bandim Health Project, International Network for the Demographic Evaluation of Populations and Their Health (INDEPTH Network), Department of Women's and Children's Health [Uppsala, Sweden], Uppsala University-International Maternal and Child Healt [Uppsala, Sweden] (IMCH), Muhimbili University of Health and Allied Sciences, University of Gothenburg (GU), Université d'Uppsala et Gothenburg, University of California [San Francisco] (UCSF), University of California, Yale School of Public Health (YSPH), Kenya Medical Research Institute (KEMRI), Medical School [Australian National University - ANU], Australian National University (ANU), The Walter and Eliza Hall Institute of Medical Research, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine (LSHTM), Epicentre [Paris] [Médecins Sans Frontières], Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Mahidol University [Bangkok]-Mahosot Hospital, Wellcome Trust-Mahosot Hospital-Oxford Tropical Medicine Research Collaboration, Mahosot Hospital-Microbiology Laboratory, Mère et enfant face aux infections tropicales (MERIT - UMR_D 216), Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5), Neuroépidémiologie Tropicale (NET), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des Maladies infectieuses et tropicales [CHU Limoges], CHU Limoges, Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford [Oxford], Shoklo Malaria Research Unit [Mae Sot, Thailand] (Faculty of Tropical Medicine), Mahidol University [Bangkok]-Mahidol Oxford Tropical Medicine Research Unit (MORU), University of Oxford [Oxford]-Mahidol University [Bangkok]-Wellcome Trust-University of Oxford [Oxford]-Wellcome Trust, Global Health Division, Menzies School of Health Research, Nagasaki University, Centre for Tropical Medicine and Global Health, University of Oxford, Mahidol Oxford Tropical Medicine Research Unit, University of Oxford [Oxford]-Mahidol University [Bangkok], Institute for Tropical Medicine = Institut für Tropenmedizin, Reisemedizin, Humanparasitolgie [Tübingen, Allemagne] (ITM), Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Department of Women and Children's Health, Uppsala University, The Walter and Eliza Hall Institute of Medical Research (WEHI), Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique (MERIT - UMR_D 216), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Centre for Tropical Medicine and Global Health [Oxford, UK], Nuffield Department of Medicine [Oxford, UK] (Big Data Institute), University of Oxford [Oxford]-University of Oxford [Oxford], Shoklo Malaria Research Unit [Mae Sot, Thailand] (SMRU), Mahidol Oxford Tropical Medicine Research Unit (MORU), University of Oxford [Oxford]-Mahidol University [Bangkok]-Wellcome Trust-University of Oxford [Oxford]-Mahidol University [Bangkok]-Wellcome Trust, Infectious diseases, APH - Global Health, APH - Quality of Care, AII - Infectious diseases, Wellcome Trust-Mahidol University [Bangkok]-University of Oxford [Oxford]-Wellcome Trust-Mahidol University [Bangkok]-University of Oxford [Oxford], and Beeson, James G.
- Subjects
Male ,Artemether, Lumefantrine Drug Combination/pharmacokinetics ,Antimalarials/pharmacokinetics ,Fluorenes/metabolism ,Antimalarials ,Pregnancy ,Health Sciences ,Humans ,Malaria, Falciparum ,Fluorenes ,Dose-Response Relationship, Drug ,Ethanolamines/metabolism ,Malaria, Falciparum/drug therapy ,Artemether, Lumefantrine Drug Combination ,Infant, Newborn ,Infant ,Public Health, Global Health, Social Medicine and Epidemiology ,Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi ,Models, Chemical ,Ethanolamines ,Child, Preschool ,Medicine ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Female - Abstract
Background - The fixed dose combination of artemether-lumefantrine (AL) is the most widely used treatment for uncomplicated Plasmodium falciparum malaria. Relatively lower cure rates and lumefantrine levels have been reported in young children and in pregnant women during their second and third trimester. The aim of this study was to investigate the pharmacokinetic and pharmacodynamic properties of lumefantrine and the pharmacokinetic properties of its metabolite, desbutyl-lumefantrine, in order to inform optimal dosing regimens in all patient populations.Methods and findings - A search in PubMed, Embase, ClinicalTrials.gov, Google Scholar, conference proceedings, and the WorldWide Antimalarial Resistance Network (WWARN) pharmacology database identified 31 relevant clinical studies published between 1 January 1990 and 31 December 2012, with 4,546 patients in whom lumefantrine concentrations were measured. Under the auspices of WWARN, relevant individual concentration-time data, clinical covariates, and outcome data from 4,122 patients were made available and pooled for the meta-analysis. The developed lumefantrine population pharmacokinetic model was used for dose optimisation through in silico simulations. Venous plasma lumefantrine concentrations 7 days after starting standard AL treatment were 24.2% and 13.4% lower in children weighing Conclusions - Our findings suggest that revised AL dosing regimens for young children and pregnant women would improve drug exposure but would require longer or more complex schedules. These dosing regimens should be evaluated in prospective clinical studies to determine whether they would improve cure rates, demonstrate adequate safety, and thereby prolong the useful therapeutic life of this valuable antimalarial treatment.
- Published
- 2018
- Full Text
- View/download PDF
20. Variants in SART3 cause a spliceosomopathy characterised by failure of testis development and neuronal defects
- Author
-
Ayers, Katie, Eggers, Stefanie, Rollo, Ben, Smith, Katherine, Davidson, Nadia, Siddall, Nicole, Zhao, Liang, Bowles, Josephine, Weiss, Karin, Zanni, Ginevra, Burglen, Lydie, Ben-Shachar, Shay, Rosensaft, Jenny, Raas-Rothschild, Annick, Jørgensen, Anne, Schittenhelm, Ralf, Huang, Cheng, Robevska, Gorjana, van den Bergen, Jocelyn, Casagranda, Franca, Cyza, Justyna, Pachernegg, Svenja, Wright, David, Bahlo, Melanie, Oshlack, Alicia, O'Brien, Terrence, Kwan, Patrick, Koopman, Peter, Hime, Gary, Girard, Nadine, Hoffmann, Chen, Shilon, Yuval, Zung, Amnon, Bertini, Enrico, Milh, Mathieu, Ben Rhouma, Bochra, Belguith, Neila, Bashamboo, Anu, Mcelreavey, Ken, Banne, Ehud, Weintrob, Naomi, Benzeev, Bruria, Sinclair, Andrew, Murdoch Children's Research Institute (MCRI), University of Melbourne, Victorian Clinical Genetics Services, Monash University [Melbourne], The Walter and Eliza Hall Institute of Medical Research (WEHI), University of Queensland [Brisbane], Technion - Israel Institute of Technology [Haifa], Bambino Gesù Children’s Hospital [Rome, Italy], CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Génétique des Troubles du Neurodéveloppement = Developmental Brain Disorders Laboratory (Equipe Inserm U1163), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Tel Aviv Sourasky Medical Center [Te Aviv], The Hebrew University Hadassah Medical School, Chaim Sheba Medical Center, Tel Aviv University (TAU), Rigshospitalet [Copenhagen], Copenhagen University Hospital, Monash University [Clayton], Peter Mac Callum Cancer Centre, Service de pédiatrie et neurologie pédiatrique, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Kaplan Medical Center [Rehovot, Israel], Université de Gabès, Université de Sfax - University of Sfax, Hôpital Charles Nicolle [Tunis], Génétique du Développement humain - Human developmental genetics, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Wolfson Medical Center, This study was supported by a National Health and Medical Research Council (NHMRC) programme grant (1074258) awarded to AS, NHMRC project grant (1156942) (K.A.), a Medical Research Future Fund Stem Cells Mission grant (MRF1201781) (K.A., B.N.R. and P.Kw), an Australian Research Council Future Fellowship (FT100100764) to M.B., A NHMRC Investigator Grant (1174040) to D.W., Agence Nationale de la Recherche funding ANR-10-LABX-73 REVIVE, ANR-17-CE14-0038-01 and ANR 20 CE14 0007 to K.M., ANR-19-CE140022 and ANR-19-CE14-0012 to A.B., G.Z. and E.B. are members of the European Reference Network for Rare Neurological Diseases - Project ID No 739510., ANR-10-LABX-0073,REVIVE,Stem Cells in Regenerative Biology and Medicine(2010), ANR-20-CE14-0007,Goldilocks,Analyse intégrée du rôle du facteur de transcription SF-1 / NR5A1 et de ses gènes cibles dépendants du dosage dans la fonction gonadique et les troubles du développement sexuel (DSD)(2020), ANR-19-CE14-0022,SexDiff,Régulation de la détermination du sexe et de la différenciation ovarienne : implications dans les troubles du développement sexuel(2019), and ANR-19-CE14-0012,RNA-SEX,Fonction de l'ARN hélicase dans la détermination du sexe chez les vertébrés et les troubles du développement du sexe chez l'homme (DSD)(2019)
- Subjects
MESH: Humans ,MESH: RNA-Binding Proteins ,MESH: Testis ,[SDV]Life Sciences [q-bio] ,MESH: Gonadal Dysgenesis ,MESH: Antigens, Neoplasm ,MESH: Induced Pluripotent Stem Cells ,MESH: Male ,MESH: Intellectual Disability - Abstract
International audience; Squamous cell carcinoma antigen recognized by T cells 3 ( SART3 ) is an RNA-binding protein with numerous biological functions including recycling small nuclear RNAs to the spliceosome. Here, we identify recessive variants in SART3 in nine individuals presenting with intellectual disability, global developmental delay and a subset of brain anomalies, together with gonadal dysgenesis in 46,XY individuals. Knockdown of the Drosophila orthologue of SART3 reveals a conserved role in testicular and neuronal development. Human induced pluripotent stem cells carrying patient variants in SART3 show disruption to multiple signalling pathways, upregulation of spliceosome components and demonstrate aberrant gonadal and neuronal differentiation in vitro. Collectively, these findings suggest that bi-allelic SART3 variants underlie a spliceosomopathy which we tentatively propose be termed INDYGON syndrome ( I ntellectual disability, N eurodevelopmental defects and D evelopmental delay with 46,X Y GON adal dysgenesis). Our findings will enable additional diagnoses and improved outcomes for individuals born with this condition.
- Published
- 2023
- Full Text
- View/download PDF
21. Ten years of CAZypedia: a living encyclopedia of carbohydrate-active enzymes
- Author
-
Štefan Janeček, Rohan J. Williams, Geoff Pincher, Darrell Cockburn, Gurvan Michel, Wataru Saburi, David R. Rose, Brian P. Rempel, Glyn R. Hemsworth, Wim Van den Ende, Jerry Ståhlberg, Leila LoLeggio, Tom Wennekes, Kiyohiko Igarashi, Cedric Montanier, Etienne Rebuffet, Naotake Konno, Harry J. Gilbert, Markus Linder, Ed Bayer, Tirso Pons, Jan-Hendrik Hehemann, Tomomi Sumida, Thierry Fontaine, Takane Katayama, Elizabeth Ficko-Blean, Florence Vincent, Zui Fujimoto, Masafumi Hidaka, Kyle Robinson, Ana R. Luís, Yuichi Sakamoto, Bernard Henrissat, Gustav Vaaje-Kolstad, Jens M. Eklöf, Ian R. Greig, Harry Brumer, Ryuichiro Suzuki, Mats Sandgren, Takashi Tonozuka, Ryszard Brzezinski, Brian L. Mark, Bareket Dassa, Haruhide Mori, Junho Lee, Vivian L. Y. Yip, Birte Svensson, Wade Abbott, Alfons K. G. Felice, Juha Rouvinen, Takayuki Ohnuma, Satoshi Kaneko, Franz J. St John, Ramon Hurtado-Guerrero, Pedro M. Coutinho, Sine Larsen, Gideon J. Davies, Yuval Shoham, Kiyotaka Fujita, Warren W. Wakarchuk, Fathima Aidha Shaikh, Alisdair B. Boraston, Breeanna R. Urbanowicz, Vincent G. H. Eijsink, Daniel Kracher, Beatrice Cobucci-Ponzano, Ethan D. Goddard-Borger, Anthony J. Clarke, David J. Vocadlo, Katsuro Yaoi, Seino A. K. Jongkees, Anna A. Kulminskaya, Roland Ludwig, Mirko M. Maksimainen, Magali Remaud-Simeon, Edward J. Taylor, Motomitsu Kitaoka, Spencer J. Williams, Shinya Fushinobu, Marco Moracci, David Wilson, Richard McLean, Toki Taira, Jean-Guy Berrin, Ran Zhang, Hiroyuki Nakai, Tracey M. Gloster, Peter J. Reilly, Wim Nerinckx, Takuya Ishida, Alicia Lammerts van Bueren, Orly Alber, Mirjam Czjzek, Kathleen Piens, Annabelle Varrot, Stephen G. Withers, Nathalie Juge, Maxime Versluys, Gerlind Sulzenbacher, Richard W. Pickersgill, Michael D. L. Suits, Agriculture and Agri-Food [Ottawa] (AAFC), Weizmann Institute of Science [Rehovot, Israël], Laboratoire d'Ingénierie des Systèmes Biologiques et des Procédés (LISBP), Institut National de la Recherche Agronomique (INRA)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), University of Victoria [Canada] (UVIC), University of British Columbia, Université de Sherbrooke (UdeS), University of Guelph, National Research Council (CNR), Pennsylvania State University (Penn State), Penn State System, Aix Marseille Université (AMU), Laboratoire de Biologie Intégrative des Modèles Marins (LBI2M), Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Station biologique de Roscoff (SBR), Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Sorbonne Université (SU), University of York, Norwegian University of Life Sciences (NMBU), University of Vienna [Vienna], University of Adelaide, Institut Pasteur [Paris], National Agriculture and Food Research Organization (NARO), Kagoshima University, University of Tokyo, Newcastle University, University of St Andrews [Scotland], The Walter and Eliza Hall Institute of Medical Research (WEHI), Simon Fraser University (SFU.ca), Max Planck Institute for Marine Microbiology, Max-Planck-Gesellschaft, University of Leeds, University of Zaragoza - Universidad de Zaragoza [Zaragoza], Slovak Academy of Sciences (SAS), Quadram Institute, University of the Ryukyus [Okinawa], Ishikawa Prefectural University, Utsunomiya University [Utsunomiya], St Petersburg Nuclear Physics Institute, University of Groningen, Aalto University, University of Copenhagen = Københavns Universitet (KU), University of Lisbon, University of Oulu, University of Manitoba [Winnipeg], University of Lethbridge, Hokkaido University [Sapporo, Japan], Niigata University, Ghent University, Kinki University, Queen Mary University of London (QMUL), Sveriges lantbruksuniversitet, National Center for Biotechnology, Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Iowa State University (ISU), Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA), University of Waterloo [Waterloo], University of Eastern Finland, Iwate Biotechnology Research Center (IBRC), Technion - Israel Institute of Technology [Haifa], United States Department of Agriculture, Wilfrid Laurier University (WLU), Architecture et fonction des macromolécules biologiques (AFMB), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Institut National de la Recherche Agronomique (INRA), Institut National de la Recherche Agronomique (INRA), RIKEN - Institute of Physical and Chemical Research [Japon] (RIKEN), Akita University, Danmarks Tekniske Universitet (DTU), University of Lincoln, Tokyo University of Agriculture and Technology (TUAT), Univ Georgia, University of Georgia [USA], Université Catholique de Louvain = Catholic University of Louvain (UCL), Centre de Recherches sur les Macromolécules Végétales (CERMAV ), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Ryerson University, Utrecht University [Utrecht], University of Melbourne, Cornell University [New York], National Institute of Advanced Industrial Science and Technology (AIST), Natural Sciences and Engineering Research Council of Canada (NSERC), Agriculture and Agri-Food (AAFC), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris] (IP), Biotechnology and Biological Sciences Research Council (BBSRC), University of Copenhagen = Københavns Universitet (UCPH), Universidade de Lisboa = University of Lisbon (ULISBOA), Universiteit Gent = Ghent University (UGENT), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Danmarks Tekniske Universitet = Technical University of Denmark (DTU), Weizmann Institute of Science, Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Recherche Agronomique (INRA), University of Victoria, Sherbrooke University, Sorbonne Universités, University of Vienna, National Agriculture and Food Research Organization, University of St Andrews, Walter and Eliza Hall Institute of Medical Research (WEHI), Slovak Academy of Sciences, Utsunomiya University, Hokkaido University, Iwate Biotechnol Res Ctr, Technion – Israel Institute of Technology, Akita Prefectural University, Université Catholique de Louvain (UCL), Centre de Recherches sur les Macromolécules Végétales (CERMAV), Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Université Grenoble Alpes (UGA), Cornell University, Laboratoire Départemental Vétérinaire et d'Hygiène Alimentaire des Hautes Alpes, and Moracci, M
- Subjects
0301 basic medicine ,History ,Carbohydrate ,CAZy ,Bioinformatics ,[SDV]Life Sciences [q-bio] ,030106 microbiology ,Polysaccharide-Lyases ,Glycobiology ,Carbohydrates ,Glycosyltransferases/chemistry ,Computational biology ,Biology ,Esterase ,Biochemistry ,History, 21st Century ,Databases ,03 medical and health sciences ,glycobiology ,Esterases/chemistry ,[SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology ,Carbohydrates/chemistry ,Glycoscience ,Databases, Protein ,ComputingMilieux_MISCELLANEOUS ,bioinformatic ,[SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Structural Biology [q-bio.BM] ,Protein ,Polysaccharide-Lyases/chemistry ,biocuration ,Esterases ,glycoscience ,Glycosyltransferases ,[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology ,bioinformatics ,21st Century ,Biocuration ,[SDV.BBM.BP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biophysics ,030104 developmental biology ,carbohydrate-active enzymes ,Encyclopedia ,Carbohydrate-active enzymes ,carbohydrate-active enzyme ,Carbohydrate active enzymes ,Glycosyltransferase - Abstract
CAZypedia was initiated in 2007 to create a comprehensive, living encyclopedia of the carbohydrate-active enzymes (CAZymes) and associated carbohydrate-binding modules involved in the synthesis, modification, and degradation of complex carbohydrates. CAZypedia is closely connected with the actively-curated CAZy database, which provides a sequence-based foundation for the biochemical, mechanistic, and structural characterization of these diverse proteins. Now celebrating its 10th anniversary online, CAZypedia is a successful example of dynamic, community-driven, and expert-based biocuration. CAZypedia is an open-access resource available at URL http://www.cazypedia.org.
- Published
- 2018
- Full Text
- View/download PDF
22. EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research
- Author
-
Eva De Smedt, Bieke Soen, Marta Monguió-Tortajada, Jasper Anckaert, Erminia Romano, Els Beghein, Hina Kalra, Alessandra Lo Cicero, Michael W. Pfaffl, Laurence Bertier, Bert Dhondt, Edward Geeurickx, Özden Akay, Lorraine O'Driscoll, Frederik J. Verweij, Alan Van Goethem, Dominik Buschmann, Olivier De Wever, Zoraida Andreu Martinez, Susanne G. van der Grein, Carina Leonelli, Vincent Hyenne, Shu Liu, Prabhu Mathiyalagan, Guillaume van Niel, Andrew D Foers, Niels Vandamme, Joeri Tulkens, Petra Leidinger, Jan Van Deun, James Brian Byrd, Suzanne Vanhauwaert, David Kim, Patrizia Agostinis, Seyma Demirsoy, Esther N. M. Nolte-‘t Hoen, Stephanie Boukouris, Aleksandra M. Dudek, Michel Bremer, Anna Cmoch, Sandra Kraemer, Kathrin Gärtner, Clotilde Théry, Hetty Helsmoortel, Farzaneh Ghazavi, Pieter Mestdagh, Dillon C. Muth, Jo Vandesompele, Grace V. Hancock, Lien Lippens, Tom Groot Kormelink, Tom A. P. Driedonks, Abdou ElSharawy, Sushma Anand, Marijke I. Zonneveld, Benjamin J. Scicluna, Joanna Kowal, Susmita Sahoo, Lesley Cheng, Safia Thaminy, Isabel Van Audenhove, Suresh Mathivanan, Ilaria Floris, Glenn Vergauwen, Geert Berx, Jan Gettemans, Johannes V. Swinnen, Yaxuan Liang, Victoria Depoorter, Shaun Martin, Alexander R. van Vliet, Natalia G. Sampaio, Martijn J. C. van Herwijnen, Bernd Giebel, Abhishek D. Garg, Bjarke Primdal-Bengtson, An Hendrix, Gloria Milani, Tamás Matusek, Liselot Mus, Annelynn Wallaert, Andrew F. Hill, Roberta Palmulli, Maarit Takatalo, Tine Baetens, Clara Casert, Janneke Boere, Monisha Samuel, Marca H. M. Wauben, Nadine Van Roy, Delphine Daveloose, Anneleen Steels, Andrea Németh, Kenneth W. Witwer, Quentin Rousseau, Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Cancer Research Institute Ghent (CRIG), Universiteit Gent = Ghent University [Belgium] (UGENT), Center for Medical Genetics, Cancer Research Institute Ghent (CRIG), Bioinformatics Institute Ghent (BIG), Cell Death Research & Therapy (CDRT) Lab, Université Catholique de Louvain = Catholic University of Louvain (UCL), Molecular and Cellular Oncology Lab, Inflammation Research Center, VIB, Department of Biomedical Molecular Biology, Cancer Research Institute Ghent (CRIG), Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Hospital Santa Cristina Instituto de Investigación Sanitaria Princesa C, Unidad de Investigación, Department of Biochemistry, Faculty of Medicine and Health Sciences, Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University [Utrecht], Institute for Transfusion Medicine, University Hospital Essen, Universität Duisburg-Essen [Essen], Animal Physiology and Immunology, School of Life Sciences, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Laboratory of Cytometry, Department of Internal Medicine, University of Michigan [Ann Arbor], University of Michigan System-University of Michigan System, Department of Biochemistry, Hôpital Lapeyronie, Institute of Clinical Molecular Biology, Kiel University, Faculty of Sciences, Division of Biochemistry, Chemistry Department, Damietta University, Physiopathologie des Adaptations Nutritionnelles (PhAN), Université de Nantes (UN)-Institut National de la Recherche Agronomique (INRA), Department of Biochemistry, Microbiology and Immunology, University of Ottawa [Ottawa], Inflammation Division, The Walter and Eliza Hall Institute of Medical Research (WEHI), Department of Medical Biology, Hacettepe University Faculty of Medicine, Partner site Munich, German Centre for Infection Research (DZIF), Research Unit Gene Vectors, Helmholtz-Zentrum München (HZM), Department of Molecular and Comparative Pathobiology and Department of Neurology, Johns Hopkins University School of Medicine, Fédération de Médecine Translationelle de Strasbourg (FMTS), LabEx Medalis, Université de Strasbourg (UNISTRA), U1109, MN3T, Institut National de la Santé et de la Recherche Médicale (INSERM), Cardiovascular Research Center, Massachusetts General Hospital [Boston], Immunité et cancer (U932), Université Paris Descartes - Paris 5 (UPD5)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris sciences et lettres (PSL), Department of Thoracic and Cardiovascular Surgery, University Hospital RWTH Aachen, Institute of Human Genetics, Universität Ulm - Ulm University [Ulm, Allemagne], German Center for Neurodegenerative Diseases, Compartimentation et dynamique cellulaires (CDC), Centre National de la Recherche Scientifique (CNRS)-Institut Curie [Paris]-Université Pierre et Marie Curie - Paris 6 (UPMC), Centre National de la Recherche Scientifique (CNRS), Institut de Biologie Valrose (IBV), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), REMAR-IVECAT Group, Germans Trias i Pujol Health Science Research Institute, Department of Genetics, Cell- and Immunobiology, Semmelweis University, School of Pharmacy and Pharmaceutical Sciences and Trinity Biomedical Sciences Institute, Trinity College Dublin, Population Health and Immunity Division, Laboratory of Lipid Metabolism and Cancer, Department of Oncology, LKI - Leuven Cancer Institute, Faculty of Biological and Environmental Sciences [Helsinki], University of Helsinki, Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, National Cancer Center, Fund for Scientific Spearheads of the Ghent University Hospital, Concerted Research Actions from Ghent University, Stichting tegen Kanker, Kom Op Tegen Kanker, H2020/COST ME-HaD, Fund for Scientific Research Flanders (FWO), Krediet aan Navorsers from FWO, Universiteit Gent = Ghent University (UGENT), Instituto de Investigacion Sanitaria del Hospital de la Princesa, Hospital Universitario de La Princesa, Universität Duisburg-Essen = University of Duisburg-Essen [Essen], Institut National de la Recherche Agronomique (INRA)-Université de Nantes (UN), Helmholtz Zentrum München = German Research Center for Environmental Health, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Curie [Paris]-Centre National de la Recherche Scientifique (CNRS), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Van Deun J., Mestdagh P., Agostinis P., Akay O., Anand S., Anckaert J., Martinez Z.A., Baetens T., Beghein E., Bertier L., Berx G., Boere J., Boukouris S., Bremer M., Buschmann D., Byrd J.B., Casert C., Cheng L., Cmoch A., Daveloose D., De Smedt E., Demirsoy S., Depoorter V., Dhondt B., Driedonks T.A.P., Dudek A., Elsharawy A., Floris I., Foers A.D., Gartner K., Garg A.D., Geeurickx E., Gettemans J., Ghazavi F., Giebel B., Kormelink T.G., Hancock G., Helsmoortel H., Hill A.F., Hyenne V., Kalra H., Kim D., Kowal J., Kraemer S., Leidinger P., Leonelli C., Liang Y., Lippens L., Liu S., Lo Cicero A., Martin S., Mathivanan S., Mathiyalagan P., Matusek T., Milani G., Monguio-Tortajada M., Mus L.M., Muth D.C., Nemeth A., Nolte-'T Hoen E.N.M., O'Driscoll L., Palmulli R., Pfaffl M.W., Primdal-Bengtson B., Romano E., Rousseau Q., Sahoo S., Sampaio N., Samuel M., Scicluna B., Soen B., Steels A., Swinnen J.V., Takatalo M., Thaminy S., Thery C., Tulkens J., Van Audenhove I., Van Der Grein S., Van Goethem A., Van Herwijnen M.J., Van Niel G., Van Roy N., Van Vliet A.R., Vandamme N., Vanhauwaert S., Vergauwen G., Verweij F., Wallaert A., Wauben M., Witwer K.W., Zonneveld M.I., De Wever O., Vandesompele J., Hendrix A., Ghent University [Belgium] (UGENT), Université Catholique de Louvain, Technical University of Munich (TUM), Physiologie des Adaptations Nutritionnelles [UMR_A1280] (PhAN), University of Ottawa [Ottawa] (uOttawa), Walter and Eliza Hall Institute of Medical Research (WEHI), Institut Curie-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), PSL Research University (PSL), Centre National de la Recherche Scientifique (CNRS)-Institut Curie-Université Pierre et Marie Curie - Paris 6 (UPMC), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes - Paris 5 (UPD5)-Institut Curie-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Nice Sophia Antipolis (... - 2019) (UNS), and Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)
- Subjects
0301 basic medicine ,minimum information ,blood-plasma ,physiology [Extracellular Vesicles] ,Biomedical Research ,Internationality ,Computer science ,phenotype ,[SDV]Life Sciences [q-bio] ,Medizin ,exosomes ,Crowdsourcing ,Bioinformatics ,Biochemistry ,03 medical and health sciences ,Extracellular Vesicles ,ultracentrifugation ,Biological property ,cancer ,ddc:610 ,resolution flow-cytometry ,Molecular Biology ,subpopulations ,business.industry ,biological-properties ,Cell Biology ,Extracellular vesicle ,Data science ,Databases, Bibliographic ,Replication (computing) ,030104 developmental biology ,cells ,business ,Biotechnology - Abstract
We argue that the field of extracellular vesicle (EV) biology needs more transparent reporting to facilitate interpretation and replication of experiments. To achieve this, we describe EV-TRACK, a crowdsourcing knowledgebase (http://evtrack.org) that centralizes EV biology and methodology with the goal of stimulating authors, reviewers, editors and funders to put experimental guidelines into practice.
- Published
- 2017
- Full Text
- View/download PDF
23. Whole genome analysis of a schistosomiasis-transmitting freshwater snail
- Author
-
Gerald M. Mkoji, Ittiprasert Wannaporn, Xiao-Jun Wu, Julia B. Carleton, Gloria I. Giraldo-Calderón, Matty Knight, Catherine S. Jones, Anthony T. Papenfuss, Elio Hideo Baba, Brian J. Raney, Richard M. Cripps, Christine Coustau, Martin T. Swain, René Feyereisen, Judith E. Humphries, Nithya Raghavan, Kathryn M. Ryan, Céline Cosseau, Karl F. Hoffmann, Michael S. Blouin, Edwin J. Routledge, TyAnna L. Lovato, Min Zhao, Olga Baron, Fabiano Sviatopolk-Mirsky Pais, Mikkel Christensens, Sandra W. Clifton, Leonid L. Moroz, Maria G. Castillo, Damian L. Trujillo, Donald P. McManus, Emanuela V. Volpi, Liana K. Jannotti-Passos, Scott P Lawton, Joanna M. Bridger, Yesid Cuesta-Astroz, Eric S. Loker, David Duval, Fernanda Ludolf, Bronwyn Rotgans, Mónica Medina, Di Liang, Benjamin Gourbal, Izinara C Rosse, Catrina Fronick, Sarah K. Buddenborg, Roberta Lima Caldeira, Umar Niazi, Aurélie Kapusta, Christoph Grunau, Scott F. Cummins, Katherine M. Buckley, Milind Misra, Matheus de Souza Gomes, LaDeana W. Hillier, Iain W. Chalmers, Guillaume Mitta, Scott J. Emrich, Kathrin K. Geyer, Wander de Jesus Jeremias, Larissa L. S. Scholte, Laurence Rodrigues do Amaral, Juliana G Assis, Jacob A. Tennessen, Emmanuel A. Pila, Patrick C. Hanington, Andrew M. Shedlock, Wesley C. Warren, Chris Botka, Sandra Grossi Gava, Coen M. Adema, Janeth J. Pena, Satwant Kaur, Chad Tomlinson, Richard Galinier, Michelle A. Gordy, Bishoy Kamel, Guilherme Oliveira, Anne E. Lockyer, Jonathan P. Rast, Andrea B. Kohn, Daniel Lawson, Richard K. Wilson, Patrick Minx, Bryony C. Bonning, Peter C. FitzGerald, Christopher J. Bayne, Omar dos Santos Carvalho, Monica Munoz-Torres, Tianfang Wang, David Rollinson, Vince Magrini, Kyle K. Biggar, Titouan Quelais, Leslie R. Noble, Utibe Bickham-Wright, Francislon Silva de Oliveira, Cédric Feschotte, Daniel J. Jackson, Joris M. Koene, Michael J. Montague, Anthony J. Walker, Lucinda Fulton, Daniel S.T. Hughes, Susan Jobling, Rob Peace, Halime D. Arican-Goktas, Nathalie Dinguirard, Timothy P. Yoshino, Mohammed Yusuf, Cesar E. Montelongo, Michael E. Geusz, Sijun Liu, Si-Ming Zhang, Kenneth B. Storey, Leon di Stephano, Yanin Limpanont, Center for Evolutionary and theoretical Immunology, Biology, The University of New Mexico [Albuquerque], The McDonnell Genome Institute (MGI), Washington University in St Louis, INSTITUTE OF BIOLOGICAL AND ENVIRONMENTAL SCIENCES, University of Aberdeen, Department of Microbiology, Immunology & Tropical Medicine and Research Center for Neglected Diseases of Poverty, George Washington University (GW), Division of Science & Mathematics, University of the District of Columbia, Fiocruz Minas - René Rachou Research Center / Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), sans affiliation, Biology Department, Medical University of South Carolina [Charleston] (MUSC), Laboratory of Bioinformatics and Molecular Analysis, Federal University of Uberlândia [Uberlândia] (UFU), Department of Life Sciences, College of Health and Life Sciences, Brunel University London [Uxbridge], Institut Sophia Agrobiotech [Sophia Antipolis] (ISA), Institut National de la Recherche Agronomique (INRA)-Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Department of Integrative Biology, Oregon State University (OSU), Department of Pathobiological Sciences, University of Wisconsin-Madison, Institute of Biochemisty and Department of Biology, Carleton University, Iowa State University (ISU), Department of Information Technology, Harvard Medical School, Harvard Medical School [Boston] (HMS), Sunnybrook Health Sciences Centre, Department of Immunology, University of Toronto, Department of Human Genetics [Salt Lake City], University of Utah, Biology, New Mexico State University, New Mexico State University, Institute of Biological, Environmental and Rural Sciences (IBERS), Aberystwyth University, EMBL-EBI, Wellcome Genome Campus, Interactions Hôtes-Pathogènes-Environnements (IHPE), Université de Perpignan Via Domitia (UPVD)-Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Faculty of Science, Health and Education, University of the Sunshine Coast, The Walter and Eliza Hall Institute for Medical Research (WEHI), Genomics and Bioinformatics Core Facility, University of Notre Dame [Indiana] (UND), Department of Plant and Environmental Sciences [Copenhagen], Faculty of Science [Copenhagen], University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU), Genome Analysis Unit, National Cancer Institute, National Institutes of Health [Bethesda] (NIH), Biological Sciences, Bowling Green State University, Bowling Green State University, IBERS, Institute of Biological, Environmental and Rural Sciences, Biotechnology and Biological Sciences Research Council, Department of Public Health Sciences, University of Alberta, University of Alberta, Department of Biology, Lawrence University, Lawrence University, Courant Research Centre Geobiology, Georg-August University of Göttingen, Georg-August-University [Göttingen], Institute of Environment, Health & Societies, Environment and Health Theme, Brunel University London, Brunel University London, Department of Biology, Pennsylvania State University (Penn State), Penn State System-Penn State System, Faculteit der Aard- en Levenswetenschappen, Vrije Universiteit, Vrije Universiteit Amsterdam [Amsterdam] (VU), The Whitney Laboratory for Marine Bioscience, University of Florida, University of Florida [Gainesville], Molecular Parasitology Laboratory, Kingston University, Kingston University, Faculty of Science, Health, Education and Engineering (USC), Molecular Parasitology Unit, Queensland Institute of Medical Research, Penn State System, Kenya Medical Research Institute (KEMRI), Department of Neuroscience (DEPARTMENT OF NEUROSCIENCE), University of Pennsylvania [Philadelphia], Lawrence Berkeley National Laboratory [Berkeley] (LBNL), Bioinformatics and Cancer Genomics lab Lorenzo and Pamela Galli, Melanoma Research Fellow Peter MacCallum Cancer Centre, Institute for Genomics and Bioinformatics [Irvine], University of California [Irvine] (UCI), University of California-University of California, Parasites and Vectors Division, London Centre for Neglected Tropical Disease Research, Natural History Museum, Department of Biomedical Sciences, Faculty of Science and Technology, University of Westminster [London] (UOW), Molecular Parasitology Laboratory, School of Life Sciences Pharmacy and Chemistry, Sequence characterization of the Biomphalaria glabrata genome was funded by NIH-NHGRI grant HG003079 to R.K.W., McDonnell Genome Institute, Washington University School of Medicine. Biomphalaria glabrata and Schistosoma mansoni were provided to some participating labs by the NIAID Schistosomiasis Resource Center (Biomedical Research Institute, Rockville, MD) through NIH-NIAID Contract HHSN272201000005I for distribution through BEI Resources. C.M.A. and E.S.L. acknowledge NIH grant P30GM110907 from the National Institute of General Medical Sciences (NIGMS). Publication costs were contributed equally by McDonnell Genome Institute, Washington University School of Medicine and the COBRE Center for Evolutionary and Theoretical Immunology (CETI) which is supported by NIH grant P30GM110907 from the National Institute of General Medical Sciences (NIGMS). E.S.L. acknowledges NIH/NIAID ROI AI101438. J.M.B., H.D.A.-G and M.K. acknowledge NIH-NIAID R01-AI0634808. M.Y. acknowledges UK BBSRC (BB/H022597/1). G.O. acknowledges support from FAPEMIG (RED-00014-14, PPM-00189-13) and CNPq (304138/2014-2, 309312/2012-4). R.L.C. acknowledges CNPq (503275/2011-5). T.P.Y. acknowledges NIH/NIAID RO1AI015503. K.F.H. and M.T.S. acknowledge BBSRC (BB/K005448/1). B.G. acknowledges ANR JCJC INVIMORY (ANR-13-JSV7-0009). S.E. acknowledges NIAID contract HHSN272201400029C. J.M.K. acknowledges the Research Council for Earth and Life Sciences (A.L.W., 819.01.007) and the Netherlands Organization for Scientific Research (NWO). R.M.C. acknowledges NIH GM061738 and support from the American Heart Association, Southwest Affiliate (14GRNT20490250). D.T. acknowledges NIH R25 GM075149. C.F. acknowledges NIH R01-GM077582. D.J.J. acknowledges D.F.G. JA2108/1-2. M.de S.G. acknowledges CNPq 479890/2013-7. K.M.B. and J.P.R. acknowledge NSERC 312221 and CIHR MOP74667. C.S.J., L.R.N., S.J., E.J.R., S.K. and A.E.L. acknowledge NC3R GO900802/1. K.K.B. and K.B.S. acknowledge NSERC 315051 and 6793, respectively. M.B. and C.J.B. acknowledge NIH RO1-AI109134. C.J.B. acknowledges NIH AI016137 and AI111201. B.R. acknowledges NHGRI 4U41HG002371. P.C.H., M.A.G. and E.A.P. acknowledge NSERC 418540. O.L.B. and Ch.C. acknowledge ANR-12-EMMA-0007-01. S.F.C. acknowledges Australian Research Council FT110100990., We thank S. Newfeld for discussion of actin evolution, N. El Sayed and H. Tettelin for discussion of HSP annotation and expression. We acknowledge access to the Metafer microscopy system at the I. Robinson Research Complex, Harwell, Rutherford Appleton Laboratory, Oxon, UK (BBSRC Professorial Fellowship, grant number BB/H022597/1)., Washington University in Saint Louis (WUSTL), The George Washington University (GW), Fiocruz Minas - René Rachou Research Center / Instituto René Rachou [Belo Horizonte, Brésil], Institut Sophia Agrobiotech (ISA), Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Recherche Agronomique (INRA), European Bioinformatics Institute [Hinxton] (EMBL-EBI), EMBL Heidelberg, Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER)-Université de Perpignan Via Domitia (UPVD), The Walter and Eliza Hall Institute of Medical Research (WEHI), University of Florida [Gainesville] (UF), Animal Ecology, and Adema, Coen M.
- Subjects
0301 basic medicine ,MESH: Sequence Analysis, DNA ,Proteome ,INTERMEDIATE HOST ,MESH: Schistosoma mansoni ,General Physics and Astronomy ,Biomphalaria ,Fresh Water ,Snail ,Genome informatics ,Genome ,Freshwater snail ,Pheromones ,MESH: Biomphalaria/parasitology ,0302 clinical medicine ,Global health ,ACTIN GENES ,MESH: Animals ,DNA sequencing ,MESH: Stress, Physiological ,MESH: Evolution, Molecular ,MESH: Pheromones ,Multidisciplinary ,biology ,INVERTEBRATE ,schistosomiase ,Schistosoma mansoni ,Corrigenda ,MESH: Gene Expression Regulation ,6. Clean water ,Multidisciplinary Sciences ,MESH: Proteome ,MESH: DNA Transposable Elements ,MESH: Fresh Water ,Science & Technology - Other Topics ,MESH: Animal Communication ,Science ,030231 tropical medicine ,MANSONI ,Zoology ,Schistosomiasis ,MESH: Host-Parasite Interactions ,General Biochemistry, Genetics and Molecular Biology ,Article ,Host-Parasite Interactions ,Evolution, Molecular ,03 medical and health sciences ,Stress, Physiological ,biology.animal ,MESH: Schistosomiasis mansoni/transmission ,[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN] ,MD Multidisciplinary ,parasitic diseases ,medicine ,Journal Article ,Biomphalaria glabrata ,Animals ,MESH: Biomphalaria/genetics ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,BIOMPHALARIA-GLABRATA ,Science & Technology ,COMPLEXITY ,escargot aquatique ,MESH: Genome ,fungi ,RECOGNITION ,General Chemistry ,Sequence Analysis, DNA ,biology.organism_classification ,medicine.disease ,bacterial infections and mycoses ,EVOLUTION ,Schistosomiasis mansoni ,Animal Communication ,[SDV.BA.ZI]Life Sciences [q-bio]/Animal biology/Invertebrate Zoology ,030104 developmental biology ,Gene Expression Regulation ,MESH: Biomphalaria/immunology ,INNATE IMMUNITY ,DNA Transposable Elements ,VERTEBRATE ,biological - Abstract
Biomphalaria snails are instrumental in transmission of the human blood fluke Schistosoma mansoni. With the World Health Organization's goal to eliminate schistosomiasis as a global health problem by 2025, there is now renewed emphasis on snail control. Here, we characterize the genome of Biomphalaria glabrata, a lophotrochozoan protostome, and provide timely and important information on snail biology. We describe aspects of phero-perception, stress responses, immune function and regulation of gene expression that support the persistence of B. glabrata in the field and may define this species as a suitable snail host for S. mansoni. We identify several potential targets for developing novel control measures aimed at reducing snail-mediated transmission of schistosomiasis., Biomphalaria glabrata is a fresh water snail that acts as a host for trematode Schistosoma mansoni that causes intestinal infection in human. This work describes the genome and transcriptome analyses from 12 different tissues of B glabrata, and identify genes for snail behavior and evolution.
- Published
- 2017
- Full Text
- View/download PDF
24. A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms
- Author
-
Benoit Witkowski, Hans-Peter Fuehrer, Garib Das Thakur, Céline Barnadas, Djibrine Djalle, Michael Ramharter, Mindy Leelawong, Wasif Ali-Khan, Harald Noedl, Bouasy Hongvanthong, Mohammad Shafiul-Alam, Hypolite Muhindo-Mavoko, Abdillahi Mohamed Hassan, Judith Straimer, Nimol Khim, Kigbafori D. Silué, Kaknika Loch, Barbara H. Stokes, Maria Dorina Bustos, Laura Berne, Dylan R. Pillai, Ayola A. Adegnika, Lin Hua Tang, Rotha Eam, Saorin Kim, Alioune Dieye, Mei Li, Carole E. Eboumbou-Moukoko, Lydie Canier, Marian Warsame, Didier Menard, David A. Fidock, Yap Boum, Lyndes Wini, Abdiqani Sheikh-Omar, Patrick Tshibangu-Wa-Tshibangu, Maman Laminou Ibrahim, Mohammad Jahirul-Karim, Malen Ken, Monique A. Dorkenoo, Sócrates Herrera, Odile Mercereau-Puijalon, Lise Musset, Valentine Duru, Eric Legrand, Maniphone Khanthavong, Pascal Ringwald, Bruno Pradines, Sandrine Houzé, Rachida Tahar, Olukemi K. Amodu, Johann Beghain, Sandie Menard, Liwang Cui, Colin J. Sutherland, Jun Hu Chen, Kesara Na-Bangchang, Khin Lin, Michael Nambozi, Rithea Leang, Jean Christophe Barale, Milijaona Randrianarivelojosia, Marcus V. G. Lacerda, Sophy Chy, Frédéric Ariey, Jean-Bosco Ouédraogo, Isabelle Morlais, Maria de Fátima Ferreira-da-Cruz, Lubin Jiang, Christophe Rogier, Jun Cao, Peter G. Kremsner, Bui Quang-Phuc, Inès Vigan-Womas, Din Syafruddin, Jetsumon Sattabongkot, Shigeyuki Kano, Abebe A. Fola, Louis Collet, Karamoko Niaré, Thierry Fandeur, Sedigheh Zakeri, Sodiomon B. Sirima, Antoine Berry, Jean Baptiste Mazarati, Fe Espino, Ghulam Rahim-Awab, Chanra Khean, Offianan Andre Toure, Institut Pasteur du Cambodge, Réseau International des Instituts Pasteur (RIIP), Génétique et Génomique des Insectes vecteurs, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Centre de Recherche Médicale de Lambaréné, Albert Schweitzer, Leiden University Medical Center (LUMC), Universiteit Leiden, International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), University of Ibadan, Nangarhar University, Mahidol University [Bangkok], The Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne, Papua New Guinea Institute for Medical Research (PNGIMR), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Mbarara University of Science and Technology [Mbarara] (MUST), Epicentre Ouganda [Mbarara] [Médecins Sans Frontières], Epicentre [Paris] [Médecins Sans Frontières], World Health Organization (WHO), country office for Thailand, Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), JiangSu University, National Institute of Parasitic Diseases, Center for Disease Control, China, Centre Hospitalier de Mayotte, Pennsylvania State University (Penn State), Penn State System, Epidemiology and Disease Control division (EDCD), Ministry of Public Health [Nepal], Institut Pasteur de Dakar, Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD), Institut Pasteur de Bangui, Université de Lomé [Togo], Université de Douala, Centre Pasteur du Cameroun, Research Institute for Tropical Medicine, Centre International de Recherches Médicales de Franceville (CIRMF), Fundação Oswaldo Cruz / Oswaldo Cruz Foundation (FIOCRUZ), University of Gondar, Institute of Parasitology [Vienna], University of Veterinary Medicine, Vienna, World Health Organisation (WHO), country office for Somalia, Caucaseco scientific research center = Centro de Investigación Científica Caucaseco, National Center for Malariology, Parasitology and Entomology, Ministry of Health [Mozambique], Hôpital Bichat - Claude Bernard, Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique (MERIT - UMR_D 216), Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5), Centre de Recherche Médicale et Sanitaire (Niamey, Niger) (CERMES), Directorate General of Health Services (DGHS), Institut Pasteur de Shanghai, Académie des Sciences de Chine - Chinese Academy of Sciences (IPS-CAS), National Center for Global Health and Medicine [Japan] (NCGM), Institut Pasteur du Laos, Instituto Leônidas e Maria Deane - Fiocruz Amazônia [Manaus, Brésil] (ILMD), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD), National Center for Malaria Control, Parasitology and Entomology, Ministry of Health of Cambodgia, Henry M. Jackson Foundation for the Advancement of Military Medicine (HJM), U.S. Naval Medical Research, The Department of Medical Research (Upper Myanmar), Rwanda Biomedical Center (RBC), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche pour le Développement [Yaoundé, Cameroun] (IRD [Cameroun]), Institut de Recherche pour le Développement (IRD), University of Kinshasa (UNIKIN), University of Antwerp (UA), Institut Pasteur de la Guyane, Thammasat University (TU), Tropical Diseases Research Center (TDRC), Université de Bamako, Medizinische Universität Wien = Medical University of Vienna, Institut de Recherche en Sciences de la Santé (IRSS) / Centre Muraz, Medicines for Malaria Venture (MMV), Université de Genève = University of Geneva (UNIGE), Global Malaria Programme, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence du Paludisme, Institut Pasteur de Madagascar, Ministry of Health and Human Services [Somalia], Centre Suisse de Recherches Scientifiques en Cote d'Ivoire [Abidjan] (CSRS-CI), Université Félix Houphouët-Boigny (UFHB), Groupe de recherche action en santé (GRAS), London School of Hygiene and Tropical Medicine (LSHTM), University of Hasanuddin, Eijkman Institute for Molecular Biology [Jakarta], Institut Pasteur de Côte d'Ivoire, Ministry of Health and Medical Services, Institut Pasteur d'Iran, Centre National de Référence du Paludisme [Cayenne, Guyane française] (CNR - laboratoire associé), Microbiologie structurale - Structural Microbiology (Microb. Struc. (UMR_3528 / U-Pasteur_5)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Columbia University Irving Medical Center (CUIMC), Institut de Recherche Biomédicale des Armées [Antenne Marseille] (IRBA), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5), Supported by the Institut Pasteur Paris, Institut Pasteur International Division, Institut Pasteur Cambodia, and the World Health Organization, by a grant (ANR-10-LABX-62-IBEID) from the French Government Investissement d’Avenir program, Laboratoire d’Excellence 'Integrative Biology of Emerging Infectious Diseases', a grant from Natixis Banques, a grant (R01I109023, to Dr. Fidock) from the National Institutes of Health, grants from the Fiocruz Fundação Oswaldo Cruz, Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro, Fundação de Amparo à Pesquisa do Estado do Amazonas, the Brazilian National Council for Scientific and Technological Development, the Agence Nationale de la Recherche (13-BSV3-0018-01 and11-BSV7-009-01), the Austrian Federal Ministry of Science, Research, and Econo-my, the Calgary Laboratory Services, the Centre International de Recherches Médicales de Franceville, the European and Developing Countries Clinical Trials Partnership (CT-2004-31070-001), the Drugs for Neglected Diseases Initiative, the Else Kroener Fresenius Stiftung, the Holger Poehlmann Stiftung, the European Community African–European Research Initiative 'IDEA' (HEALTH-F3-2009-241642), the Fonds Wetenschappelijk Onderzoek, the Vlaamse Interuniversitaire Raad–Universitaire Ontwikkelingssamenwerking, the Belgian Technical Cooperation in Democratic Republic of Congo, the European Community Seventh Framework Program (FP7/2007-2013, 242095, and 223601), the European Commission (REGPOT-CT-2011-285837-STRONGER), the Ministère de la Santé Publique du Niger (Laboratoire National de Référence Résistance aux Antipaludiques), the Foundation of National Science and Technology Major Program (2012ZX10004-220), the French Ministry of Health (Institut National de Veille Sanitaire), the Global Fund to Fight AIDS, Tuberculosis and Malaria, the 5% Initiative program (French Ministry of Foreign Affairs, France Expertise Internationale, 12INI109), the Institut Pasteur de Madagascar, the Government of the Philippines, the Institut de Recherche pour le Développement, the Foundation des Treilles, the Délégation Générale pour l’Armement (PDH-2-NRBC-4-B1-402), the Institut Pasteur de Bangui, the International Society for Health Research and Training, the Malaria Research Initiative Bandarban, Vienna, International Centre for Diarrhoeal Disease Research, Bangladesh, the Médecins sans Frontières (Centre Opérationnel Paris, France), Medicines for Malaria Venture, the National Research Council of Thailand, the Thammasat University, the National Natural Science Foundation of China (81271870, 81361120405, and 81271863), the Natural Science Foundation of Jiangsu Province (BK20130114 and BK20150001), the Jiangsu Science and Technology Department (BM2015024), the National Institutes of Health (R01 AI11646601, AI109023, and ICEMR U19AI089702, U19AI089672), the Pasteur Institute of Iran, the Malaria Division of the Iranian Center for Diseases Management and Control, Public Health England (Malaria Reference Service Contract), the Government of Rwanda, the U.S. Department of Defense Armed Forces Health Surveillance Center, Global Emerging Infections Surveillance and Response System (P0463-14-N6), the Fogarty International Center of the National Institutes of Health training (D43 TW007393), the Mahidol-Oxford Research Unit, the Government of Japan (Science and Technology Agency, Agency for Medical Research and Development, Japan International Cooperation Agency, and Science and Technology Research Partnership for Sustainable Development), and the President’s Malaria Initiative of the U.S. Agency for International Development., The KARMA Consortium, ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), ANR-13-BSV3-0018,MALARTRES,Résistance de Plasmodium aux antipaludiques de la famille des artémisinines(2013), ANR-13-BSV7-0009,NEBEDIV,Le rôle des ennemis naturels dans la diversité béta des arbres tropicaux(2013), European Project: CT-2004-31070-001,EDCCTP, European Project: HEALTH-F3-2009-24164,IDEA, European Project: FP7/2007-2013, 24209,FP7, European Project: FP7/2007-2013, 22360,FP7, European Project: 285837,EC:FP7:REGPOT,FP7-REGPOT-2011-1,STRONGER(2011), European Project: 242095,EC:FP7:HEALTH,FP7-HEALTH-2009-single-stage,EVIMALAR(2009), European Project: 223601,EC:FP7:HEALTH,FP7-HEALTH-2007-B,MALVECBLOK(2009), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), CHU Toulouse [Toulouse], Fundação Oswaldo Cruz (FIOCRUZ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Genève (UNIGE), INSB-INSB-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence du Paludisme [Cayenne, Guyane française] (CNR), Université Paris Diderot - Paris 7 (UPD7)-Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Eberhard Karls Universität Tübingen, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia., Centre International de Recherches Médicales de Franceville, Caucaseco scientific research center, Mère et enfant face aux infections tropicales (MERIT - UMR_D 216), National Center for Global Health and Medicine (NCGM), Instituto Leônidas e Maria Deane (ILMD), Centre de Physiopathologie Toulouse Purpan ex IFR 30 et IFR 150 (CPTP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche pour le Développement [Yaoundé], Centre Suisse de Recherches Scientifiques en Côte d'Ivoire, Eijkman Institute for Molecular Biology, Laboratoire de Parasitologie, Centre National de Référence du Paludisme - Région Antilles-Guyane, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-WHO Collaborating Center for Surveillance of Antimalarial Drug Resistance, Institut Pasteur [Paris]-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), ANR-10-LABX-62-IBEID,IBEID,Laboratoire d'Excellence 'Integrative Biology of Emerging Infectious Diseases'(2010), Van geertruyden, Jean-Pierre, and KARMA Consortium
- Subjects
0301 basic medicine ,Nonsynonymous substitution ,MESH: Sequence Analysis, DNA ,Endemic Diseases ,MESH: Asia, Southeastern ,Drug Resistance ,Protozoan Proteins ,Drug resistance ,MESH: Genotype ,Lactones ,0302 clinical medicine ,Genotype ,Artemisinin ,Malaria, Falciparum ,MESH: Protozoan Proteins ,Asia, Southeastern ,MESH: Plasmodium falciparum ,Genetics ,biology ,MESH: Malaria, Falciparum ,General Medicine ,Artemisinins ,MESH: China ,3. Good health ,MESH: Endemic Diseases ,MESH: Drug Resistance ,Algorithms ,MESH: Lactones ,medicine.drug ,China ,MESH: Mutation ,030231 tropical medicine ,030106 microbiology ,Plasmodium falciparum ,MESH: Algorithms ,03 medical and health sciences ,parasitic diseases ,MESH: Artemisinins ,MESH: Polymorphism, Genetic ,medicine ,Humans ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,Allele ,Polymorphism, Genetic ,MESH: Humans ,Haplotype ,Sequence Analysis, DNA ,medicine.disease ,biology.organism_classification ,Virology ,Mutation ,Human medicine ,Malaria - Abstract
Comment inK13-Propeller Mutations and Malaria Resistance, http://www.nejm.org/doi/full/10.1056/NEJMe1604520; International audience; BACKGROUND:Recent gains in reducing the global burden of malaria are threatened by the emergence of Plasmodium falciparum resistance to artemisinins. The discovery that mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domains are the major determinant of resistance has provided opportunities for monitoring such resistance on a global scale.METHODS:We analyzed the K13-propeller sequence polymorphism in 14,037 samples collected in 59 countries in which malaria is endemic. Most of the samples (84.5%) were obtained from patients who were treated at sentinel sites used for nationwide surveillance of antimalarial resistance. We evaluated the emergence and dissemination of mutations by haplotyping neighboring loci.RESULTS:We identified 108 nonsynonymous K13 mutations, which showed marked geographic disparity in their frequency and distribution. In Asia, 36.5% of the K13 mutations were distributed within two areas--one in Cambodia, Vietnam, and Laos and the other in western Thailand, Myanmar, and China--with no overlap. In Africa, we observed a broad array of rare nonsynonymous mutations that were not associated with delayed parasite clearance. The gene-edited Dd2 transgenic line with the A578S mutation, which expresses the most frequently observed African allele, was found to be susceptible to artemisinin in vitro on a ring-stage survival assay.CONCLUSIONS:No evidence of artemisinin resistance was found outside Southeast Asia and China, where resistance-associated K13 mutations were confined. The common African A578S allele was not associated with clinical or in vitro resistance to artemisinin, and many African mutations appear to be neutral. (Funded by Institut Pasteur Paris and others.).
- Published
- 2016
- Full Text
- View/download PDF
25. C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3 -Mutant Leukemia
- Author
-
Marie Sabatier, Rudy Birsen, Laura Lauture, Sarah Mouche, Paolo Angelino, Jonas Dehairs, Lea Goupille, Ismael Boussaid, Mael Heiblig, Emeline Boet, Ambrine Sahal, Estelle Saland, Juliana C. Santos, Marc Armengol, Miranda Fernandez-Serrano, Thomas Farge, Guillaume Cognet, Federico Simonetta, Corentin Pignon, Antoine Graffeuil, Celine Mazzotti, Herve Avet-Loiseau, Oceane Delos, Justine Bertrand-Michel, Amelie Chedru, Vilma Dembitz, Paolo Gallipoli, Natasha S. Anstee, Sun Loo, Andrew H. Wei, Martin Carroll, Armelle Goubard, Remy Castellano, Yves Collette, Francois Vergez, Veronique Mansat-De Mas, Sarah Bertoli, Suzanne Tavitian, Muriel Picard, Christian Recher, Nathalie Bourges-Abella, Fanny Granat, Olivier Kosmider, Pierre Sujobert, Benoit Colsch, Carine Joffre, Lucille Stuani, Johannes V. Swinnen, Herve Guillou, Gael Roue, Nawad Hakim, Anne S. Dejean, Petros Tsantoulis, Clement Larrue, Didier Bouscary, Jerome Tamburini, Jean-Emmanuel Sarry, Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Faculté de médecine [Genève], Swiss Institute of Bioinformatics [Lausanne] (SIB), Université de Lausanne = University of Lausanne (UNIL), Leuven Cancer Institute [Leuven, Belgium] (LKI), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Hospices Civils de Lyon (HCL), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Josep Carreras Leukaemia Research Institute (IJC), MetaboHUB-MetaToul, MetaboHUB-Génopole Toulouse Midi-Pyrénées [Auzeville] (GENOTOUL), Université de Toulouse (UT)-Université de Toulouse (UT)-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Queen Mary University of London (QMUL), The Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne, Peter MacCallum Cancer Center, Perelman School of Medicine, University of Pennsylvania, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Régional d'Exploration Fonctionnelle et Ressources Expérimentales (CREFRE), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Leuven Cancer Institute (LKI), Leuven, Belgium, ToxAlim (ToxAlim), Université de Toulouse (UT)-Ecole d'Ingénieurs de Purpan (INP - PURPAN), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université de Genève = University of Geneva (UNIGE), and 2018/Ligue Nationale de Lutte contre le Cancer C57799/A27964/Cancer Research UK (CRUK) Institut National Du Cancer (INCa)
- Subjects
Oncology ,[SDV]Life Sciences [q-bio] - Abstract
Although transcription factor CCAAT-enhancer binding protein α (C/EBPα) is critical for normal and leukemic differentiation, its role in cell and metabolic homeostasis is largely unknown in cancer. Here, multiomics analyses uncovered a coordinated activation of C/EBPα and Fms-like tyrosine kinase 3 (FLT3) that increased lipid anabolism in vivo and in patients with FLT3-mutant acute myeloid leukemia (AML). Mechanistically, C/EBPα regulated the fatty acid synthase (FASN)–stearoyl-CoA desaturase (SCD) axis to promote fatty acid (FA) biosynthesis and desaturation. We further demonstrated that FLT3 or C/EBPα inactivation decreased monounsaturated FA incorporation to membrane phospholipids through SCD downregulation. Consequently, SCD inhibition enhanced susceptibility to lipid redox stress that was exploited by combining FLT3 and glutathione peroxidase 4 inhibition to trigger lipid oxidative stress, enhancing ferroptotic death of FLT3-mutant AML cells. Altogether, our study reveals a C/EBPα function in lipid homeostasis and adaptation to redox stress, and a previously unreported vulnerability of FLT3-mutant AML to ferroptosis with promising therapeutic application. Significance: FLT3 mutations are found in 30% of AML cases and are actionable by tyrosine kinase inhibitors. Here, we discovered that C/EBPα regulates FA biosynthesis and protection from lipid redox stress downstream mutant-FLT3 signaling, which confers a vulnerability to ferroptosis upon FLT3 inhibition with therapeutic potential in AML. This article is highlighted in the In This Issue feature, p. 1501
- Published
- 2023
- Full Text
- View/download PDF
26. A subfamily classification to choreograph the diverse activities within glycoside hydrolase family 31
- Author
-
Thimali Arumapperuma, Jinling Li, Bastian Hornung, Niccolay Madiedo Soler, Ethan D. Goddard-Borger, Nicolas Terrapon, Spencer J. Williams, The Walter and Eliza Hall Institute of Medical Research (WEHI), Architecture et fonction des macromolécules biologiques (AFMB), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and University of Melbourne
- Subjects
enzyme ,glycobiology ,kinetics ,[SDV]Life Sciences [q-bio] ,glycosidase ,Cell Biology ,bioinformatics ,Molecular Biology ,Biochemistry ,Research Article - Abstract
International audience; The Carbohydrate-Active Enzyme classification groups enzymes that breakdown, assemble, or decorate glycans into protein families based on sequence similarity. The glycoside hydrolases (GH) are arranged into over 170 enzyme families, with some being very large and exhibiting distinct activities/specificities towards diverse substrates. Family GH31 is a large family that contains more than 20,000 sequences with a wide taxonomic diversity. Less than 1% of GH31 members are biochemically characterized and exhibit many different activities that include glycosidases, lyases, and transglycosidases. This diversity of activities limits our ability to predict the activities and roles of GH31 family members in their host organism and our ability to exploit these enzymes for practical purposes. Here, we established a subfamily classification using sequence similarity networks that was further validated by a structural analysis. While sequence similarity networks provide a sequence-based separation, we obtained good segregation between activities among the subfamilies. Our subclassification consists of 20 subfamilies with sixteen subfamilies containing at least one characterized member and eleven subfamilies that are monofunctional based on the available data. We also report the biochemical characterization of a member of the large subfamily 2 (GH31_2) that lacked any characterized members: RaGH31 from Rhodoferax aquaticus is an α-glucosidase with activity on a range of disaccharides including sucrose, trehalose, maltose, and nigerose. Our subclassification provides improved predictive power for the vast majority of uncharacterized proteins in family GH31 and highlights the remaining sequence space that remains to be functionally explored.
- Published
- 2023
- Full Text
- View/download PDF
27. COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey
- Author
-
Hoff, Leonardo Santos, Ravichandran, Naveen, Shinjo, Samuel Katsuyuki, Day, Jessica, Sen, Parikshit, Junior, Jucier Gonçalves, Lilleker, James B., Joshi, Mrudula, Agarwal, Vishwesh, Kardes, Sinan, Kim, Minchul, Milchert, Marcin, Makol, Ashima, Gheita, Tamer, Salim, Babur, Velikova, Tsvetelina, Gracia-Ramos, Abraham Edgar, Parodis, Ioannis, Selva O'Callaghan, Albert, Nikiphorou, Elena, Tan, Ai Lyn, Chatterjee, Tulika, Cavagna, Lorenzo, Saavedra, Miguel A., Ziade, Nelly, Knitza, Johannes, Kuwana, Masataka, Nune, Arvind, Distler, Oliver, Cansu, Döndü Üsküdar, Traboco, Lisa, Wibowo, Suryo Angorro Kusumo, Tehozol, Erick Adrian Zamora, Serrano, Jorge Rojas, La Torre, Ignacio García-De, Wincup, Chris, Pauling, John D., Chinoy, Hector, Agarwal, Vikas, Aggarwal, Rohit, Gupta, Latika, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Hoff LS] School of Medicine, Universidade Potiguar (UnP), Natal, Brazil. [Ravichandran N] Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. [Shinjo SK, Junior JG] Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil. [Day J] Department of Rheumatology, Royal Melbourne Hospital, Parkville, Australia. Walter and Eliza Hall Institute of Medical Research, Parkville, Australia. Department of Medical Biology, University of Melbourne, Parkville, Australia. [Sen P] Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, India. [O'Callaghan AS] Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Malalties autoimmunitàries ,Autoimmune diseases ,Immunology ,Immune System Diseases::Autoimmune Diseases [DISEASES] ,enfermedades del sistema inmune::enfermedades autoinmunes [ENFERMEDADES] ,COVID-19 ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunoterapia activa::vacunación [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Breakthrough infection ,SARS-CoV-2 vaccination ,Rheumatology ,Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunotherapy, Active::Vaccination [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,Immunology and Allergy ,Idiopathic inflammatory myopathies ,COVID-19 (Malaltia) - Vacunació - Abstract
Objectives We aimed to compare the spectrum and severity of COVID-19 and vaccine breakthrough infections (BIs) among patients with IIMs, other systemic autoimmune and inflammatory diseases (SAIDs), and healthy controls (HCs). Methods This is a cross-sectional study with data from the COVAD study, a self-reported online global survey that collected demographics, COVID-19 history, and vaccination details from April to September 2021. Adult patients with at least one COVID-19 vaccine dose were included. BIs were defined as infections occurring > 2 weeks after any dose of vaccine. Characteristics associated with BI were analyzed with a multivariate regression analysis. Results Among 10,900 respondents [42 (30–55) years, 74%-females, 45%-Caucasians] HCs were (47%), SAIDs (42%) and IIMs (11%). Patients with IIMs reported fewer COVID-19 cases before vaccination (6.2%-IIM vs 10.5%-SAIDs vs 14.6%-HC; OR = 0.6, 95% CI 0.4–0.8, and OR = 0.3, 95% CI 0.2–0.5, respectively). BIs were uncommon (1.4%-IIM; 1.9%-SAIDs; 3.2%-HC) and occurred in 17 IIM patients, 13 of whom were on immunosuppressants, and 3(18%) required hospitalization. All-cause hospitalization was higher in patients with IIM compared to HCs [23 (30%) vs 59 (8%), OR = 2.5, 95% CI 1.2–5.1 before vaccination, and 3 (18%) vs 9 (5%), OR = 2.6, 95% CI 1.3–5.3 in BI]. In a multivariate regression analysis, age 30–60 years was associated with a lower odds of BI (OR = 0.7, 95% CI 0.5–1.0), while the use of immunosuppressants had a higher odds of BI (OR = 1.6, 95% CI 1.1–2.7). Conclusions Patients with IIMs reported fewer COVID-19 cases than HCs and other SAIDs, but had higher odds of all-cause hospitalization from COVID-19 than HCs. BIs were associated with the use of immunosuppressants and were uncommon in IIMs.
- Published
- 2023
- Full Text
- View/download PDF
28. Subtype and pathway specific responses to anticancer compounds in breast cancer
- Author
-
Heidi S. Feiler, Eric A. Collisson, Joel Greshock, Mary Ann Hardwicke, Elizabeth Purdom, Gordon B. Mills, Bryan T. Hennessy, Lakshmi Jakkula, Pete Smith, Yinghui Guan, James E. Korkola, John W. Park, Joe W. Gray, Nicholas J. Wang, William J. Gibb, Kurtis E. Bachman, Denise M. Wolf, Lyubomir T. Vassilev, Henrik Bengtsson, Kenneth Wood, Stephen C. Benz, Zhi Hu, Anguraj Sadanandam, Nora Bayani, François Pepin, Frances Tong, Terence P. Speed, Laura M. Heiser, Sam Ng, Steffen Durinck, Theodore C. Goldstein, Joshua M. Stuart, Wen-Lin Kuo, Richard M. Neve, Paul T. Spellman, Jessica Billig, David Haussler, Sophia Lewis, Safiyyah Ziyad, Richard Wooster, Andrea Dueregger, Pierre Neuvial, Laurence J. Marton, Life Science Division [LBNL Berkeley], Lawrence Berkeley National Laboratory [Berkeley] (LBNL), Department of Biomolecular Engineering, University of California [Santa Cruz] (UCSC), University of California-University of California, Center for Biomolecular Science and Engineering, Department of Statistics [Berkeley], University of California [Berkeley], Laboratoire Statistique et Génome (SG), Institut National de la Recherche Agronomique (INRA)-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS), Department of Epidemiology and Biostatistics, University of California, San Francisco, University of California [San Francisco] (UCSF), Cytokinetics Inc, Oncology, Millenium Pharmaceuticals, Hoffmann-La Roche Ltd, Department of Systems Biology, The University of Texas MD Anderson Cancer Center, The University of Texas M.D. Anderson Cancer Center [Houston], GlaxoSmithKline, Glaxo Smith Kline, Division of Hematology-Oncology, Progen Pharmaceuticals, The Walter and Eliza Hall Institute of Medical Research (WEHI), The Walter and Eliza Hall Institute of Medical Research, Howard Hughes Medical Institute [Santa Cruz] (HHMI), Center for Biomolecular Science & Engineering, Department of Computer Science [Alabama], University of Alabama [Tuscaloosa] (UA), University of California-University of California-Howard Hughes Medical Institute (HHMI), University of California [Santa Cruz] (UC Santa Cruz), University of California (UC)-University of California (UC), University of California [Berkeley] (UC Berkeley), University of California [San Francisco] (UC San Francisco), F. Hoffmann-La Roche [Basel], and Howard Hughes Medical Institute (HHMI)-University of California [Santa Cruz] (UC Santa Cruz)
- Subjects
Transcription, Genetic ,[SDV]Life Sciences [q-bio] ,Gene Dosage ,Antineoplastic Agents ,Breast Neoplasms ,Genomics ,Biology ,Pharmacology ,Models, Biological ,Gene dosage ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Breast cancer cell line ,Transcription (biology) ,Cell Line, Tumor ,medicine ,Drug response ,Humans ,Breast Cancer Special Feature ,030304 developmental biology ,0303 health sciences ,Multidisciplinary ,medicine.disease ,[SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM] ,3. Good health ,Cell culture ,030220 oncology & carcinogenesis ,Cancer research ,Female ,Drug Screening Assays, Antitumor ,Signal transduction ,Signal Transduction - Abstract
International audience; Breast cancers are comprised of molecularly distinct subtypes that may respond differently to pathway-targeted therapies now under development. Collections of breast cancer cell lines mirror many of the molecular subtypes and pathways found in tumors, suggesting that treatment of cell lines with candidate therapeutic compounds can guide identification of associations between molecular subtypes, pathways, and drug response. In a test of 77 therapeutic compounds, nearly all drugs showed differential responses across these cell lines, and approximately one third showed subtype-, pathway-, and/or genomic aberration-specific responses. These observations suggest mechanisms of response and resistance and may inform efforts to develop molecular assays that predict clinical response.
- Published
- 2012
29. Guidelines for mouse and human DC generation
- Author
-
Manfred B. Lutz, Shafaqat Ali, Cindy Audiger, Stella E. Autenrieth, Luciana Berod, Venetia Bigley, Laura Cyran, Marc Dalod, Jan Dörrie, Diana Dudziak, Georgina Flórez‐Grau, Lucila Giusiano, Gloria J. Godoy, Marion Heuer, Anne B. Krug, Christian H. K. Lehmann, Christian T. Mayer, Shalin H. Naik, Stefanie Scheu, Gerty Schreibelt, Elodie Segura, Kristin Seré, Tim Sparwasser, Jurjen Tel, Huaming Xu, Martin Zenke, University of Würzburg, Institute of Medical Microbiology and Hospital Hygiene (University of Düsseldorf), Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], The Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), University of Tübingen, University Medical Center of the Johannes Gutenberg-University Mainz, Newcastle University [Newcastle], Centre d'Immunologie de Marseille - Luminy (CIML), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Universitätsklinikum Erlangen [Erlangen], Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), University Hospital Erlangen = Uniklinikum Erlangen, Radboud Institute for Molecular Life Sciences [Nijmegen, the Netherlands], Ludwig Maximilian University [Munich] (LMU), Universität Duisburg-Essen = University of Duisburg-Essen [Essen], Immunité et cancer (U932), Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris sciences et lettres (PSL), Universitätsklinikum RWTH Aachen - University Hospital Aachen [Aachen, Germany] (UKA), Rheinisch-Westfälische Technische Hochschule Aachen University (RWTH), Eindhoven University of Technology [Eindhoven] (TU/e), University of Duisburg-Essen, and Dalod, Marc
- Subjects
In vitro ,Immunology ,Generation ,Immunology and Allergy ,endritic cells ,[SDV.IMM.II] Life Sciences [q-bio]/Immunology/Innate immunity ,[SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunity ,Isolation - Abstract
European journal of immunology (2022). doi:10.1002/eji.202249816, Published by Wiley-VCH, Weinheim
- Published
- 2022
- Full Text
- View/download PDF
30. Single-cell RNA sequencing of Plasmodium vivax sporozoites reveals stage- and species-specific transcriptomic signatures
- Author
-
Anthony A. Ruberto, Caitlin Bourke, Amélie Vantaux, Steven P. Maher, Aaron Jex, Benoit Witkowski, Georges Snounou, Ivo Mueller, Département Parasites et Insectes vecteurs - Department of Parasites and Insect Vectors, Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), The Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne, Institut Pasteur du Cambodge, Réseau International des Instituts Pasteur (RIIP), University of Georgia [USA], Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Infectious Diseases Models for Innovative Therapies (IDMIT), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Institut de Biologie François JACOB (JACOB), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), This work was supported by the Agence Nationale de la Recherche (https://anr.fr, ANR-17-CE13-0025 to A.A.R, G.S., I.M.), the National Health and Medical Research Council of Australia (www.nhmrc.gov.au, NHMRC, 1092789 and 1134989 to I.M.), National Institute of Allergy and Infectious Diseases (www.nih.niaid.gov, 5U19AI129392 to I.M), and a NHMRC Principal Research Fellowship (www.nhmrc.gov.au, 1155075 to I.M)., ANR-17-CE13-0025,IMHyp,Recherches sur l'Hypnozoïte du Paludisme(2017), Snounou, Georges, and Recherches sur l'Hypnozoïte du Paludisme - - IMHyp2017 - ANR-17-CE13-0025 - AAPG2017 - VALID
- Subjects
MESH: Humans ,Sequence Analysis, RNA ,MESH: Transcriptome ,Public Health, Environmental and Occupational Health ,MESH: Sporozoites ,Malaria ,MESH: Plasmodium vivax ,Infectious Diseases ,Sporozoites ,Anopheles ,Malaria, Vivax ,MESH: Sequence Analysis, RNA ,Animals ,Humans ,sporozoite ,MESH: Animals ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,Malaria, Falciparum ,Plasmodium vivax ,transcriptome ,hypnozoite ,[SDV.MP.PAR] Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology - Abstract
Background Plasmodium vivax sporozoites reside in the salivary glands of a mosquito before infecting a human host and causing malaria. Previous transcriptome-wide studies in populations of these parasite forms were limited in their ability to elucidate cell-to-cell variation, thereby masking cellular states potentially important in understanding malaria transmission outcomes. Methodology/Principal findings In this study, we performed transcription profiling on 9,947 P. vivax sporozoites to assess the extent to which they differ at single-cell resolution. We show that sporozoites residing in the mosquito’s salivary glands exist in distinct developmental states, as defined by their transcriptomic signatures. Additionally, relative to P. falciparum, P. vivax displays overlapping and unique gene usage patterns, highlighting conserved and species-specific gene programs. Notably, distinguishing P. vivax from P. falciparum were a subset of P. vivax sporozoites expressing genes associated with translational regulation and repression. Finally, our comparison of single-cell transcriptomic data from P. vivax sporozoite and erythrocytic forms reveals gene usage patterns unique to sporozoites. Conclusions/Significance In defining the transcriptomic signatures of individual P. vivax sporozoites, our work provides new insights into the factors driving their developmental trajectory and lays the groundwork for a more comprehensive P. vivax cell atlas.
- Published
- 2022
- Full Text
- View/download PDF
31. Plasmodium vivax malaria serological exposure markers: Assessing the degree and implications of cross-reactivity with P. knowlesi
- Author
-
Rhea J. Longley, Matthew J. Grigg, Kael Schoffer, Thomas Obadia, Stephanie Hyslop, Kim A. Piera, Narimane Nekkab, Ramin Mazhari, Eizo Takashima, Takafumi Tsuboi, Matthias Harbers, Kevin Tetteh, Chris Drakeley, Chetan E. Chitnis, Julie Healer, Wai-Hong Tham, Jetsumon Sattabongkot, Michael T. White, Daniel J. Cooper, Giri S. Rajahram, Bridget E. Barber, Timothy William, Nicholas M. Anstey, Ivo Mueller, The Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne, Charles Darwin University [Australia], Hub Bioinformatique et Biostatistique - Bioinformatics and Biostatistics HUB, Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Epidémiologie et Analyse des Maladies Infectieuses - Infectious Disease Epidemiology and Analytics, Ehime University [Matsuyama, Japon], RIKEN Center for Integrative Medical Sciences [Yokohama] (RIKEN IMS), RIKEN - Institute of Physical and Chemical Research [Japon] (RIKEN), London School of Hygiene and Tropical Medicine (LSHTM), Biologie de Plasmodium et Vaccins - Malaria Parasite Biology and Vaccines, Mahidol University [Bangkok], University of Cambridge [UK] (CAM), Hospital Queen Elizabeth II [Kota Kinabalu, Sabah, Malaysia], Infectious Diseases Society Kota Kinabalu Sabah [Malaysia], Gleneagles Hospital [Kota Kinabalu, Sabah, Malaysia], WEHI Innovation Fund (R.L., I.M.). Clinical Trials Funding: Malaysian Ministry of Health (grant number BP00500420), the Asia Pacific Malaria Elimination Network (108-07), and the Australian National Health and Medical Research Council (NHMRC, 1037304, 1045156, 115680). NHMRC Fellowships to N.M.A. #1135820, M.J.G. #1138860, and R.L. #1173210. NHMRC grants #1092789, #1134989, #1132975 and #1043345 (I.M.). M.J.G. was also supported by the Australian Centre for International Agricultural Research (Grant# LS-2019-116)., Tham, Wai-Hong [0000-0001-7950-8699], and Apollo - University of Cambridge Repository
- Subjects
antibody cross-reactivity ,species cross-reactivity ,General Biochemistry, Genetics and Molecular Biology ,Article ,Malaria ,serosurveillance ,serological exposure markers ,Immunoglobulin G ,Malaria, Vivax ,antibodies ,Humans ,Plasmodium knowlesi ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Plasmodium vivax ,malaria elimination ,ComputingMilieux_MISCELLANEOUS - Abstract
Serological markers are a promising tool for surveillance and targeted interventions for Plasmodium vivax malaria. P. vivax is closely related to the zoonotic parasite P. knowlesi, which also infects humans. P. vivax and P. knowlesi are co-endemic across much of South East Asia, making it important to design serological markers that minimize cross-reactivity in this region. To determine the degree of IgG cross-reactivity against a panel of P. vivax serological markers, we assayed samples from human patients with P. knowlesi malaria. IgG antibody reactivity is high against P. vivax proteins with high sequence identity with their P. knowlesi ortholog. IgG reactivity peaks at 7 days post-P. knowlesi infection and is short-lived, with minimal responses 1 year post-infection. We designed a panel of eight P. vivax proteins with low levels of cross-reactivity with P. knowlesi. This panel can accurately classify recent P. vivax infections while reducing misclassification of recent P. knowlesi infections.
- Published
- 2022
- Full Text
- View/download PDF
32. Infanticide vs. inherited cardiac arrhythmias
- Author
-
Vicki Athanasopoulos, Todor Arsov, Matthew C. Cook, Sui Rong Wayne Chen, Peter J. Schwartz, Ruiwu Wang, Deborah DiSilvestre, Hariharan Raju, David A Wallace, Richard Redon, Marcin Adamski, Helene Halkjær Jensen, Ivy E. Dick, Antony Kaspi, Melanie Bahlo, Matthew A. Field, Jinhong Wei, Lia Crotti, Michael Toft Overgaard, Mette Nyegaard, Haloom Rafehi, Bárbara B Ribeiro de Oliveira-Mendes, Carola G. Vinuesa, Yafei Zhang, Flavien Charpentier, Isabelle Baró, Malene Brohus, Aalborg University [Denmark] (AAU), Australian National University (ANU), Columbia University Irving Medical Center (CUIMC), Aarhus University [Aarhus], Istituto Auxologico Italiano, Università degli Studi di Milano-Bicocca [Milano] (UNIMIB), unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Macquarie University [Sydney], University of Maryland School of Medicine, University of Maryland System, University of Calgary, The Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne, Brohus, M, Arsov, T, Wallace, D, Jensen, H, Nyegaard, M, Crotti, L, Adamski, M, Zhang, Y, Field, M, Athanasopoulos, V, Baró, I, Ribeiro de Oliveira-Mendes, B, Redon, R, Charpentier, F, Raju, H, Disilvestre, D, Wei, J, Wang, R, Rafehi, H, Kaspi, A, Bahlo, M, Dick, I, Chen, S, Cook, M, Vinuesa, C, Overgaard, M, and Schwartz, P
- Subjects
Tachycardia ,MED/03 - GENETICA MEDICA ,Infanticide ,030204 cardiovascular system & hematology ,Ventricular tachycardia ,Ryanodine receptor 2 ,Sudden cardiac death ,ACTIVATION ,BSN ,Death, Sudden ,0302 clinical medicine ,VENTRICULAR-TACHYCARDIA ,AcademicSubjects/MED00200 ,CALMODULIN ,Child ,0303 health sciences ,High-Throughput Nucleotide Sequencing ,Smothering ,Sudden unexpected death ,3. Good health ,Child, Preschool ,Cardiology ,Female ,INACTIVATION ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,Channelopathies and Cardiomyopathies ,Long QT syndrome ,Catecholaminergic polymorphic ventricular tachycardia ,03 medical and health sciences ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Clinical Research ,Physiology (medical) ,Internal medicine ,BASSOON ,medicine ,Humans ,030304 developmental biology ,MUTATIONS ,business.industry ,Calmodulinopathy ,Australia ,Infant ,Cardiac arrhythmia ,Arrhythmias, Cardiac ,Ryanodine Receptor Calcium Release Channel ,MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE ,medicine.disease ,Death, Sudden, Cardiac ,Tachycardia, Ventricular ,CALM2 ,business - Abstract
Aims In 2003, an Australian woman was convicted by a jury of smothering and killing her four children over a 10-year period. Each child died suddenly and unexpectedly during a sleep period, at ages ranging from 19 days to 18 months. In 2019 we were asked to investigate if a genetic cause could explain the children’s deaths as part of an inquiry into the mother’s convictions. Methods and results Whole genomes or exomes of the mother and her four children were sequenced. Functional analysis of a novel CALM2 variant was performed by measuring Ca2+-binding affinity, interaction with calcium channels and channel function. We found two children had a novel calmodulin variant (CALM2 G114R) that was inherited maternally. Three genes (CALM1-3) encode identical calmodulin proteins. A variant in the corresponding residue of CALM3 (G114W) was recently reported in a child who died suddenly at age 4 and a sibling who suffered a cardiac arrest at age 5. We show that CALM2 G114R impairs calmodulin's ability to bind calcium and regulate two pivotal calcium channels (CaV1.2 and RyR2) involved in cardiac excitation contraction coupling. The deleterious effects of G114R are similar to those produced by G114W and N98S, which are considered arrhythmogenic and cause sudden cardiac death in children. Conclusion A novel functional calmodulin variant (G114R) predicted to cause idiopathic ventricular fibrillation, catecholaminergic polymorphic ventricular tachycardia, or mild long QT syndrome was present in two children. A fatal arrhythmic event may have been triggered by their intercurrent infections. Thus, calmodulinopathy emerges as a reasonable explanation for a natural cause of their deaths., Graphical Abstract
- Published
- 2020
- Full Text
- View/download PDF
33. Developing sero-diagnostic tests to facilitate Plasmodium vivax Serological Test-and-Treat approaches: modeling the balance between public health impact and overtreatment
- Author
-
Thomas, Obadia, Narimane, Nekkab, Leanne J, Robinson, Chris, Drakeley, Ivo, Mueller, Michael T, White, Malaria : parasites et hôtes - Malaria : parasites and hosts, Institut Pasteur [Paris] (IP), Epidémiologie et Analyse des Maladies Infectieuses - Infectious Disease Epidemiology and Analytics, Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Hub Bioinformatique et Biostatistique - Bioinformatics and Biostatistics HUB, Swiss Tropical and Public Health Institute [Basel], University of Basel (Unibas), The Walter and Eliza Hall Institute of Medical Research (WEHI), Burnet Institute [Melbourne, Victoria], University of Melbourne, London School of Hygiene and Tropical Medicine (LSHTM), This work is supported by the Bill and Melinda Gates Foundation grants (INV009103 & VISPA INV024368) and NHMRC grants (GNT1102297 & GNT1171795) and is part of the International Centers of Excellence for Malaria Research program 'Understanding, tracking and eliminating malaria transmission in the Asia–Pacific Region,' funded by the National Institutes of Health, MD, US (grant 1U19AI129392-01). IM is supported by an NHMRC Principal Research Fellowship (GNT1155075). MTW is supported by the Agence Nationale de la Recherche Investissement d’Avenir Programme, Laboratoire d’Excellence 'Integrative Biology of Emerging Infectious Diseases' (ANR-10-LABX-62-IBEID) and INCEPTION program (ANR-16-CONV-0005). LJR is supported by an NHMRC Career Development Fellowship (GNT1161627)., ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), ANR-16-CONV-0005,INCEPTION,Institut Convergences pour l'étude de l'Emergence des Pathologies au Travers des Individus et des populatiONs(2016), Institut Pasteur [Paris], and Institut Pasteur [Paris]-Université Paris Cité (UPC)
- Subjects
Overtreatment ,Diagnostic Tests, Routine ,Test development ,Plasmodium vivax malaria ,Serological test-and-treat ,Modeling ,General Medicine ,Public health interventions ,parasitic diseases ,Humans ,Serologic Tests ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Public Health ,Plasmodium vivax - Abstract
Background Eliminating Plasmodium vivax will require targeting the hidden liver-stage reservoir of hypnozoites. This necessitates new interventions balancing the benefit of reducing vivax transmission against the risk of over-treating some individuals with drugs which may induce haemolysis. By measuring antibodies to a panel of vivax antigens, a strategy of serological-testing-and-treatment (PvSeroTAT) can identify individuals with recent blood-stage infections who are likely to carry hypnozoites and target them for radical cure. This provides a potential solution to selectively treat the vivax reservoir with 8-aminoquinolines. Methods PvSeroTAT can identify likely hypnozoite carriers with ~80% sensitivity and specificity. Diagnostic test sensitivities and specificities ranging 50–100% were incorporated into a mathematical model of vivax transmission to explore how they affect the risks and benefits of different PvSeroTAT strategies involving hypnozoiticidal regimens. Risk was measured as the rate of overtreatment and benefit as reduction of community-level vivax transmission. Results Across a wide range of combinations of diagnostic sensitivity and specificity, PvSeroTAT was substantially more effective than bloodstage mass screen and treat strategies and only marginally less effective than mass drug administration. The key test characteristic determining of the benefit of PvSeroTAT strategies is diagnostic sensitivity, with higher values leading to more hypnozoite carriers effectively treated and greater reductions in vivax transmission. The key determinant of risk is diagnostic specificity: higher specificity ensures that a lower proportion of uninfected individuals are unnecessarily treated with primaquine. These relationships are maintained in both moderate and low transmission settings (qPCR prevalence 10% and 2%). Increased treatment efficacy and adherence can partially compensate for lower test performance. Multiple rounds of PvSeroTAT with a lower performing test may lead to similar or higher reductions in vivax transmission than fewer rounds with a higher performing test, albeit with higher rate of overtreatment. Conclusions At current performance, PvSeroTAT is predicted to be a safe and efficacious option for targeting the hypnozoite reservoir towards vivax elimination. P. vivax sero-diagnostic tests should aim for both high performance and ease of use in the field. The target product profiles informing such development should thus reflect the trade-offs between impact, overtreatment, and ease of programmatic implementation.
- Published
- 2022
- Full Text
- View/download PDF
34. Innate lymphoid cells and cancer
- Author
-
Nicolas Jacquelot, Cyril Seillet, Eric Vivier, Gabrielle T. Belz, University Health Network, Princess Margaret Cancer Centre [Toronto, Canada], The Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne, Centre d'Immunologie de Marseille - Luminy (CIML), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Innate Pharma, Hôpital de la Timone [CHU - APHM] (TIMONE), University of Queensland - The Diamantina Institute, University of Queensland [Brisbane], and ANR-17-RHUS-0007,PIONEER,Precision Immuno-Oncology for advanced Non small cell lung cancer patients with PD-1 ICI Resistance(2017)
- Subjects
Killer Cells, Natural ,Neoplasms ,[SDV]Life Sciences [q-bio] ,Immunology ,Humans ,Immunology and Allergy ,Tumour immunology ,Innate lymphoid cells ,Immunotherapy ,Lymphocytes ,Immunity, Innate - Abstract
The innate lymphoid cell (ILC) family is composed of natural killer (NK) cells, ILC1, ILC2 and ILC3, which participate in immune responses to virus, bacteria, parasites and transformed cells. ILC1, ILC2 and ILC3 subsets are mostly tissue-resident, and are profoundly imprinted by their organ of residence. They exhibit pleiotropic effects, driving seemingly paradoxical responses such as tissue repair and, alternatively, immunopathology toward allergens and promotion of tumorigenesis. Despite this, a trickle of studies now suggests that non-NK ILCs may not be overwhelmingly tumorigenic and could potentially be harnessed to drive anti-tumor responses. Here, we examine the pleiotropic behavior of ILCs in cancer and begin to unravel the gap in our knowledge that exposes a new horizon for thinking about modifying ILCs and targeting them for immunotherapy.
- Published
- 2022
- Full Text
- View/download PDF
35. Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death
- Author
-
Andrew H. Wei, Kevin Tran, Kristin K. Brown, Fiona C. Brown, Caitlin L. Rowe, Tatiana Cañeque, Ali Motazedian, Sebastian Müller, Giovanna Pomilio, Raphaël Rodriguez, Andrew G. Cox, Kate McArthur, Mathilde Poplineau, Marian L. Burr, Enid Y.N. Lam, Sylvain Garciaz, Mark A. Dawson, Lorey K. Smith, Brian Liddicoat, Georg Ramm, Estelle Duprez, Kah Lok Chan, Yih-Chih Chan, Sarah-Jane Dawson, Andrew A Guirguis, James Anton Kuzich, Veronique Litalien, David C.S. Huang, Laura MacPherson, University of Melbourne, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Chimie biologique des membranes et ciblage thérapeutique (CBMCT - UMR 3666 / U1143), Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Monash University [Melbourne], The Walter and Eliza Hall Institute of Medical Research (WEHI), and Duprez, Estelle
- Subjects
Programmed cell death ,Iron ,Apoptosis ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,In vivo ,[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN] ,Humans ,Caspase ,bcl-2-Associated X Protein ,030304 developmental biology ,0303 health sciences ,Cell Death ,biology ,Chemistry ,Venetoclax ,[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology ,Metabolism ,In vitro ,Mitochondria ,3. Good health ,Cell biology ,bcl-2 Homologous Antagonist-Killer Protein ,Oncology ,030220 oncology & carcinogenesis ,Cancer cell ,biology.protein ,[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN] - Abstract
Cancer cell metabolism is increasingly recognized as providing an exciting therapeutic opportunity. However, a drug that directly couples targeting of a metabolic dependency with the induction of cell death in cancer cells has largely remained elusive. Here we report that the drug-like small-molecule ironomycin reduces the mitochondrial iron load, resulting in the potent disruption of mitochondrial metabolism. Ironomycin promotes the recruitment and activation of BAX/BAK, but the resulting mitochondrial outer membrane permeabilization (MOMP) does not lead to potent activation of the apoptotic caspases, nor is the ensuing cell death prevented by inhibiting the previously established pathways of programmed cell death. Consistent with the fact that ironomycin and BH3 mimetics induce MOMP through independent nonredundant pathways, we find that ironomycin exhibits marked in vitro and in vivo synergy with venetoclax and overcomes venetoclax resistance in primary patient samples. Significance: Ironomycin couples targeting of cellular metabolism with cell death by reducing mitochondrial iron, resulting in the alteration of mitochondrial metabolism and the activation of BAX/BAK. Ironomycin induces MOMP through a different mechanism to BH3 mimetics, and consequently combination therapy has marked synergy in cancers such as acute myeloid leukemia. This article is highlighted in the In This Issue feature, p. 587
- Published
- 2022
- Full Text
- View/download PDF
36. Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection
- Author
-
Pelleau, Stéphane, Woudenberg, Tom, Rosado, Jason, Donnadieu, Françoise, Garcia, Laura, Obadia, Thomas, Gardais, Soazic, Elgharbawy, Yasmine, Velay, Aurelie, Gonzalez, Maria, Nizou, Jacques Yves, Khelil, Nizar, Zannis, Konstantinos, Cockram, Charlotte, Merkling, Sarah Hélène, Meola, Annalisa, Kerneis, Solen, Terrier, Benjamin, de Seze, Jerome, Planas, Delphine, Schwartz, Olivier, Dejardin, François, Petres, Stéphane, von Platen, Cassandre, Pellerin, Sandrine Fernandes, Arowas, Laurence, de Facci, Louise Perrin, Duffy, Darragh, Cheallaigh, Clíona Ní, Dunne, Jean, Conlon, Niall, Townsend, Liam, Duong, Veasna, Auerswald, Heidi, Pinaud, Laurie, Tondeur, Laura, Backovic, Marija, Hoen, Bruno, Fontanet, Arnaud, Mueller, Ivo, Fafi-Kremer, Samira, Bruel, Timothée, White, Michael, Epidémiologie et Analyse des Maladies Infectieuses - Infectious Disease Epidemiology and Analytics, Institut Pasteur [Paris] (IP), Malaria : parasites et hôtes - Malaria : parasites and hosts, Santé publique : épidémiologie & sciences de l'information biomédicale (ED 393), Sorbonne Université (SU), Département de Biologie Computationnelle - Department of Computational Biology, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Strasbourg, Institut Mutualiste de Montsouris (IMM), Régulation spatiale des Génomes - Spatial Regulation of Genomes, Interactions Virus-Insectes - Insect-Virus Interactions (IVI), Virologie Structurale - Structural Virology, Epidémiologie et modélisation de la résistance aux antimicrobiens - Epidemiology and modelling of bacterial escape to antimicrobials (EMAE), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Université de Paris, Paris, France, Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), CIC Strasbourg (Centre d’Investigation Clinique Plurithématique (CIC - P) ), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nouvel Hôpital Civil de Strasbourg-Hôpital de Hautepierre [Strasbourg], Virus et Immunité - Virus and immunity (CNRS-UMR3569), Plateforme technologique Production et purification de protéines recombinantes – Production and Purification of Recombinant Proteins Technological Platform (PPR), Centre de Recherche Translationnelle - Center for Translational Science (CRT), Investigation Clinique et d’Accès aux Ressources Biologiques (Plate-forme) - Clinical Investigation and Access to BioResources (ICAReB), Immunologie Translationnelle - Translational Immunology lab, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Trinity College Dublin, Institut Pasteur du Cambodge, Réseau International des Instituts Pasteur (RIIP), Epidémiologie des Maladies Emergentes - Emerging Diseases Epidemiology, Pasteur-Cnam Risques infectieux et émergents (PACRI), Institut Pasteur [Paris] (IP)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Institut Pasteur [Paris] (IP)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM), Direction de la recherche médicale de l'Institut Pasteur, Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM), The Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne, Vaccine Research Institute [Créteil, France] (VRI), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), This work was supported by the European Research Council (MultiSeroSurv ERC Starting Grant 852373, MW), l’Agence Nationale de la Recherche and Fondation pour la Recherche Médicale (CorPopImm, MW), and the Institut Pasteur International Network (CoronaSeroSurv, MW). JR was supported by the Pasteur Paris University (PPU) International PhD Program. CC was supported by the European Research Council 771813. MB, AL and HA were supported by the « URGENCE COVID-19 » fundraising campaign of Institut Pasteur. HA is supported by Centre for International Migration and Development. NC and CNC are part-funded by a Science Foundation Ireland (SFI) grant, Grant Code 20/SPP/3685. LT has been awarded the Irish ClinicalAcademic Training (ICAT) Programme, supported by the Wellcome Trust and the Health Research Board (Grant Number 203930/B/16/Z), the Health Service Executive, National Doctors Training and Planning and the Health and Social Care, Research and Development Division, Northern Ireland (https://icatprogramme.org/). MB and AM were supported by Institut Pasteur TaskForce funding (TooLab project). IM is supported by a NHMRC Principal Research Fellowship. SFK lab is funded by Strasbourg University Hospitals (SeroCoV-HUS, PRI 7782), the Agence Nationale de la Recherche (ANR-18-CE17-0028), Laboratoire d'Excellence TRANSPLANTEX (ANR-11-LABX-0070_TRANSPLANTEX), and Institut National de la Santé et de la Recherche Médicale (UMR_S1109)., ANR-20-COVI-0052,CorPopImm,Évaluer l'immunité contre SARS-CoV-2 à l'échelle de la population grâce aux tests sérologiques(2020), ANR-18-CE17-0028,HuMABK,Les anticorps monoclonaux humains : une Nouvelle approche thérapeutique contre l'infection par le virus BK et les maladies associées(2018), ANR-11-LABX-0070,TRANSPLANTEX,Nouveaux loci d'histocompatibilité/biomarqueurs en transplantation humaine: de la découverte à l'app(2011), European Project: 852373,ERC-2019-STG,MultiSeroSurv(2020), European Project: 771813,ERC-2017-COG,SynarchiC(2018), Institut Pasteur [Paris], Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC), Virus et Immunité - Virus and immunity, Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université (HESAM)-HESAM Université (HESAM)-Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université (HESAM)-HESAM Université (HESAM), HESAM Université (HESAM), Vaccine Research Institute (VRI), and HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] (CNAM)
- Subjects
Male ,Aucun ,Antibodies, Viral ,time since infection ,MESH: Aged, 80 and over ,Antibody Specificity ,Seroepidemiologic Studies ,MESH: COVID-19 ,Aged, 80 and over ,MESH: Immunoglobulin G ,MESH: Aged ,MESH: Middle Aged ,seroprevalence ,MESH: Kinetics ,Middle Aged ,MESH: Antibody Formation ,AcademicSubjects/MED00290 ,MESH: Young Adult ,surveillance ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Female ,France ,Adult ,antibody kinetics ,Adolescent ,SARS-SoV-2 ,Sensitivity and Specificity ,Young Adult ,Major Article ,Humans ,Serologic Tests ,MESH: SARS-CoV-2 ,MESH: Antibody Specificity ,Aged ,MESH: Adolescent ,MESH: Humans ,MESH: Seroepidemiologic Studies ,SARS-CoV-2 ,MESH: Serologic Tests ,COVID-19 ,MESH: Adult ,MESH: Male ,MESH: Sensitivity and Specificity ,MESH: France ,Kinetics ,sero-prevalence ,Immunoglobulin G ,Antibody Formation ,MESH: Female ,MESH: Antibodies, Viral - Abstract
Background Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a complex antibody response that varies by orders of magnitude between individuals and over time. Methods We developed a multiplex serological test for measuring antibodies to 5 SARS-CoV-2 antigens and the spike proteins of seasonal coronaviruses. We measured antibody responses in cohorts of hospitalized patients and healthcare workers followed for up to 11 months after symptoms. A mathematical model of antibody kinetics was used to quantify the duration of antibody responses. Antibody response data were used to train algorithms for estimating time since infection. Results One year after symptoms, we estimate that 36% (95% range, 11%–94%) of anti-Spike immunoglobulin G (IgG) remains, 31% (95% range, 9%–89%) anti-RBD IgG remains, and 7% (1%–31%) of anti-nucleocapsid IgG remains. The multiplex assay classified previous infections into time intervals of 0–3 months, 3–6 months, and 6–12 months. This method was validated using data from a seroprevalence survey in France, demonstrating that historical SARS-CoV-2 transmission can be reconstructed using samples from a single survey. Conclusions In addition to diagnosing previous SARS-CoV-2 infection, multiplex serological assays can estimate the time since infection, which can be used to reconstruct past epidemics., Longitudinal follow-up of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reveals differences in the duration of antibodies to multiple antigens. Mathematical models of antibody waning and statistical algorithms can estimate an individual’s time since SARS-CoV-2 infection, and previous transmission waves in a population.
- Published
- 2021
- Full Text
- View/download PDF
37. A specialized tyrosine-based endocytosis signal in MR1 controls antigen presentation to MAIT cells
- Author
-
Hui Jing Lim, Jacinta M. Wubben, Cristian Pinero Garcia, Sebastian Cruz-Gomez, Jieru Deng, Jeffrey Y.W. Mak, Abderrahman Hachani, Regan J. Anderson, Gavin F. Painter, Jesse Goyette, Shanika L. Amarasinghe, Matthew E. Ritchie, Antoine Roquilly, David P. Fairlie, Katharina Gaus, Jamie Rossjohn, Jose A. Villadangos, Hamish E.G. McWilliam, KERANDEL-DION, Céline, University of Melbourne, Monash University [Clayton], University of New South Wales [Sydney] (UNSW), University of Queensland [Brisbane], Victoria University of Wellington, The Walter and Eliza Hall Institute of Medical Research (WEHI), Centre hospitalier universitaire de Nantes (CHU Nantes), Team 6 : Impact of acute inflammation on host pathogen interactions and lung homeostasis (U1064 Inserm - CR2TI), Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology (U1064 Inserm - CR2TI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), and Cardiff University
- Subjects
[SDV] Life Sciences [q-bio] ,Minor Histocompatibility Antigens ,Antigen Presentation ,[SDV]Life Sciences [q-bio] ,Histocompatibility Antigens Class I ,Adaptor Protein Complex 2 ,Humans ,Tyrosine ,Cell Biology ,Vitamins ,Lymphocyte Activation ,Endocytosis ,Mucosal-Associated Invariant T Cells - Abstract
International audience; MR1 is a highly conserved microbial immune-detection system in mammals. It captures vitamin B–related metabolite antigens from diverse microbes and presents them at the cell surface to stimulate MR1-restricted lymphocytes including mucosal-associated invariant T (MAIT) cells. MR1 presentation and MAIT cell recognition mediate homeostasis through host defense and tissue repair. The cellular mechanisms regulating MR1 cell surface expression are critical to its function and MAIT cell recognition, yet they are poorly defined. Here, we report that human MR1 is equipped with a tyrosine-based motif in its cytoplasmic domain that mediates low affinity binding with the endocytic adaptor protein 2 (AP2) complex. This interaction controls the kinetics of MR1 internalization from the cell surface and minimizes recycling. We propose MR1 uses AP2 endocytosis to define the duration of antigen presentation to MAIT cells and the detection of a microbial metabolic signature by the immune system.
- Published
- 2021
- Full Text
- View/download PDF
38. Amplification of Duffy binding protein-encoding gene allows Plasmodium vivax to evade host anti-DBP humoral immunity
- Author
-
Lenore L. Carias, Benoit Witkowski, Saorin Kim, Christopher L. King, Camille Roesch, Nimol Khim, Ivo Mueller, Chetan E. Chitnis, Jean Popovici, Amélie Vantaux, Malaria Molecular Epidemiology, Institut Pasteur du Cambodge, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Malaria Translational Research Unit (MTRU), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut Pasteur [Paris], Case Western Reserve University [Cleveland], Département Parasites et Insectes vecteurs - Department of Parasites and Insect Vectors, Institut Pasteur [Paris], The Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne, Louis Stokes Cleveland Veterans Affairs Medical Center, This work was supported by the International Centers of Excellence for Malaria Research program from the National Institutes of Health, grant 1U19AI129392-01., Malaria Molecular Epidemiology (MMEU), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut Pasteur [Paris] (IP), and Institut Pasteur [Paris] (IP)
- Subjects
0301 basic medicine ,Erythrocytes ,Reticulocytes ,Plasmodium vivax ,Gene Dosage ,Protozoan Proteins ,General Physics and Astronomy ,Antibodies, Protozoan ,MESH: Gene Dosage ,0302 clinical medicine ,Parasite immune evasion ,MESH: Immune Evasion ,MESH: Immunity, Humoral ,lcsh:Science ,MESH: Protozoan Proteins ,MESH: Receptors, Cell Surface ,Multidisciplinary ,biology ,MESH: Erythrocytes ,3. Good health ,MESH: Plasmodium vivax ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,MESH: RNA, Protozoan ,Antibody ,Pathogens ,RNA, Protozoan ,medicine.drug_class ,Science ,030231 tropical medicine ,Antigens, Protozoan ,Receptors, Cell Surface ,Monoclonal antibody ,Gene dosage ,General Biochemistry, Genetics and Molecular Biology ,Article ,Antibodies ,03 medical and health sciences ,Antigen ,Immunity ,MESH: Antibodies, Blocking ,parasitic diseases ,Antigenic variation ,medicine ,Malaria, Vivax ,Humans ,MESH: Antibodies, Protozoan ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,RNA, Messenger ,Antibodies, Blocking ,Immune Evasion ,MESH: RNA, Messenger ,MESH: Humans ,MESH: Malaria, Vivax ,General Chemistry ,biology.organism_classification ,MESH: Reticulocytes ,Virology ,Malaria ,Immunity, Humoral ,MESH: Duffy Blood-Group System ,030104 developmental biology ,Humoral immunity ,biology.protein ,lcsh:Q ,Duffy Blood-Group System ,MESH: Antigens, Protozoan - Abstract
Antigenic variation, the capacity to produce a range of variable antigens, is a well-described strategy of Plasmodium and other parasites to evade host immunity. Here, we show that gene amplification is an additional evasion mechanism used by Plasmodium vivax to escape humoral immunity targeting PvDBP, the key ligand involved in reticulocyte invasion. PvDBP gene amplification leads to increased mRNA levels and protects P. vivax in vitro against invasion inhibitory human monoclonal antibodies targeting a conserved binding domain of DBP. Patient samples suggest that parasites with increased pvdbp copy number are able to infect individuals with naturally acquired antibodies highly blocking the binding of PvDBP to the Duffy receptor. These results show that gene copy number variation affect the parasite’s ability to evade anti-PvDBP humoral immunity., Duffy binding protein (DBP) of Plasmodium vivax is important for invasion and is a potential vaccine candidate. Here, the authors show that PvDBP gene amplification protects P vivax in vitro against invasion inhibitory human monoclonal antibodies and is associated to infection of patients with PvDBP binding inhibitory antibodies.
- Published
- 2020
- Full Text
- View/download PDF
39. Sequence diversity and evolution of a group of iflaviruses associated with ticks
- Author
-
Daveu, Romain, Hervet, Caroline, Sigrist, Louane, Sassera, Davide, Jex, Aaron, Labadie, Karine, Aury, Jean-Marc, Plantard, Olivier, Rispe, Claude, Biologie, Epidémiologie et analyse de risque en Santé Animale (BIOEPAR), École nationale vétérinaire, agroalimentaire et de l'alimentation Nantes-Atlantique (ONIRIS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Dipartimento di Biologia e Biotecnologie 'Lazzaro Spallanzani' = Department of Biology and Biotechnology [Univ di Pavia] (DBB UNIPV), Università degli Studi di Pavia = University of Pavia (UNIPV), The Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne, Genoscope - Centre national de séquençage [Evry] (GENOSCOPE), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Génomique métabolique (UMR 8030), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS), This work was supported by the Genoscope, the Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA) and France Génomique (ANR-10-INBS-09-08), by the Italian Ministry of Education, University and Research (MIUR): Dipartimenti di Eccellenza Program (2018–2022) – Dept. of Biology and Biotechnology 'L. Spallanzani', University of Pavia (to D.S.), and by a grant from the Institut Carnot France Futur Elevage (XENOBIOTICK project)., Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Dipartimento di Biologia e Biotecnologie ‘Lazzaro Spallanzani’, University of Pavia, University of Pavia, and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université d'Évry-Val-d'Essonne (UEVE)
- Subjects
Ticks ,[SDV]Life Sciences [q-bio] ,Mutation ,Viruses ,parasitic diseases ,Animals ,Original Article ,Genome, Viral ,Biological Evolution ,Phylogeny ,Cell Line - Abstract
International audience; We studied a group of tick-associated viruses with characteristics of members of the family Iflaviridae , a family of viruses frequently found in arthropods. Our aim was to gain insight into the evolutionary dynamics of this group of viruses, which may be linked to the biology of ticks. We explored assembled RNA-Seq data sets for different species of ticks. We identified members of five different iflavirus species, four of them novel, and discovered nine new genome sequences, including variants. Five variants represented a virus species associated with Ixodes ricinus . Unexpectedly, a sequence found in the Ixodes scapularis cell line ISE6 was nearly identical to the sequences of I. ricinus variants, suggesting a contamination of this cell line by I. ricinus material. Analysing patterns of substitutions between these variants, we detected a strong excess of synonymous mutations, suggesting evolution under strong positive selection. The phylogenies of the viruses and of their tick hosts were not congruent, suggesting recurrent host changes across tick genera during their evolution. Overall, our work constitutes a step in the understanding of the interactions between this family of viruses and ticks.
- Published
- 2021
- Full Text
- View/download PDF
40. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma
- Author
-
Ariel Munitz, Kylie Luong, Andrew N. J. McKenzie, Jaring Schreuder, Wei Shi, Minyu Wang, Sharon Grisaru-Tal, Melissa J. Davis, Paul S. Foster, Joseph A. Trapani, Bogoljub Ciric, Sean Macdonald, Kevin Y. T. Thia, Soroor Hediyeh-Zadeh, Cynthia Louis, Ian P. Wicks, Stephen L. Nutt, Qiutong Huang, Jonathan Cebon, Shengbo Zhang, Daniel H.D. Gray, Paul J Neeson, Andreas Behren, Philip M. Hansbro, Cyril Seillet, Michael Chopin, Nicolas Jacquelot, Viktor Umansky, Angela Pizzolla, Joanna R Groom, Fernando Souza-Fonseca-Guimaraes, Mary J Camilleri, Tristan Molden-Hauer, Yang Liao, Eric Vivier, Carolyn A. de Graaf, Gabrielle T. Belz, DUMENIL, Anita, The Walter and Eliza Hall Institute of Medical Research (WEHI), Princess Margaret Cancer Centre [Toronto, Canada], University of Melbourne, Peter MacCallum Cancer Centre [Melbourne, Australie], Olivia Newton-John Cancer Research Institute [Heidelberg, VIC, Australia], La Trobe University, Tel Aviv University (TAU), University of Queensland [Brisbane], German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Ruprecht-Karls-University [Heidelberg, Germany], Jefferson (Philadelphia University + Thomas Jefferson University), University of Newcastle [Australia] (UoN), Centenary Institute [Sidney], The University of Sidney, University of Technology Sydney (UTS), MRC Laboratory of Molecular Biology [Cambridge, UK] (LMB), University of Cambridge [UK] (CAM)-Medical Research Council, Ludwig Institute for Cancer Research, Centre d'Immunologie de Marseille - Luminy (CIML), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Innate Pharma, Hôpital de la Timone [CHU - APHM] (TIMONE), and University of Newcastle [Callaghan, Australia] (UoN)
- Subjects
0301 basic medicine ,Cytotoxicity, Immunologic ,Male ,Programmed cell death ,Skin Neoplasms ,[SDV]Life Sciences [q-bio] ,medicine.medical_treatment ,Immunology ,Programmed Cell Death 1 Receptor ,Melanoma, Experimental ,Article ,Antibodies ,03 medical and health sciences ,Th2 Cells ,0302 clinical medicine ,Immune system ,Neoplasms ,Cell Line, Tumor ,Antineoplastic Combined Chemotherapy Protocols ,Immunology and Allergy ,Medicine ,Animals ,Humans ,Lymphocytes ,Immune Checkpoint Inhibitors ,Tissue homeostasis ,Mice, Knockout ,business.industry ,Melanoma ,Innate lymphoid cell ,Granulocyte-Macrophage Colony-Stimulating Factor ,medicine.disease ,Interleukin-33 ,Immunity, Innate ,Blockade ,[SDV] Life Sciences [q-bio] ,Interleukin 33 ,Eosinophils ,Mice, Inbred C57BL ,Chemotaxis, Leukocyte ,030104 developmental biology ,Cytokine ,Phenotype ,1107 Immunology ,Cancer research ,Cytokines ,Female ,business ,030215 immunology - Abstract
International audience; Group 2 innate lymphoid cells (ILC2s) are essential to maintain tissue homeostasis. In cancer, ILC2s can harbor both pro-tumorigenic and anti-tumorigenic functions, but we know little about their underlying mechanisms or whether they could be clinically relevant or targeted to improve patient outcomes. Here, we found that high ILC2 infiltration in human melanoma was associated with a good clinical prognosis. ILC2s are critical producers of the cytokine granulocyte-macrophage colony-stimulating factor, which coordinates the recruitment and activation of eosinophils to enhance antitumor responses. Tumor-infiltrating ILC2s expressed programmed cell death protein-1, which limited their intratumoral accumulation, proliferation and antitumor effector functions. This inhibition could be overcome in vivo by combining interleukin-33-driven ILC2 activation with programmed cell death protein-1 blockade to significantly increase antitumor responses. Together, our results identified ILC2s as a critical immune cell type involved in melanoma immunity and revealed a potential synergistic approach to harness ILC2 function for antitumor immunotherapies.
- Published
- 2021
- Full Text
- View/download PDF
41. Estimated impact of tafenoquine for Plasmodium vivax control and elimination in Brazil: A modelling study
- Author
-
Nekkab, Narimane, Lana, Raquel, Lacerda, Marcus, Obadia, Thomas, Siqueira, André, Monteiro, Wuelton, Villela, Daniel, Mueller, Ivo, White, Michael, Malaria : parasites et hôtes - Malaria : parasites and hosts, Institut Pasteur [Paris] (IP), Fundação Oswaldo Cruz / Oswaldo Cruz Foundation (FIOCRUZ), Réseau International des Instituts Pasteur (RIIP), Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD), Universidade do Estado do Amazonas (UEA), The Walter and Eliza Hall Institute of Medical Research (WEHI), NN, MW, DV, and RL received funding from the Medicines for Malaria Venture (https://www.mmv.org/). NN has been in part supported by the Pasteur-Roux-Cantarini Fellowship by Institut Pasteur (https://research.pasteur.fr/en/call/pasteur-roux-cantarini-fellowship_call-for-application_2019-autumn-session/). NN, IM, and MW are supported by the Supporting Preparedness in the Asia-Pacific Region through Knowledge (SPARK) project under the ASEAN-Pacific Infectious Disease and Response program (APIDDaR) (https://www.spark.edu.au/). IM is supported by NHMRC Principal Research Fellowship (GNT1155075) (https://www.nhmrc.gov.au/funding/find-funding/research-fellowships). DV is a CNPq/Brazil research fellow (https://www.gov.br/cnpq/pt-br). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., and The authors would like thank Penny Grewal Daumerie, Elodie Jambert, Melanie Larson, Gonzalo Domingo, and Alexandre Menezes for their valued contributions, support, and fruitful discussions.
- Subjects
Male ,Plasmodium ,Epidemiology ,MESH: Disease Eradication ,Primaquine ,Geographical locations ,Medical Conditions ,MESH: Aged, 80 and over ,Drug Metabolism ,MESH: Child ,Medicine and Health Sciences ,Prevalence ,Secondary Prevention ,MESH: Aminoquinolines ,Child ,MESH: Models, Theoretical ,Aged, 80 and over ,MESH: Aged ,MESH: Middle Aged ,MESH: Secondary Prevention ,Pharmaceutics ,MESH: Infant, Newborn ,Drugs ,Chloroquine ,Middle Aged ,MESH: Infant ,MESH: Plasmodium vivax ,MESH: Young Adult ,Child, Preschool ,Aminoquinolines ,Medicine ,Female ,Brazil ,Research Article ,Adult ,Adolescent ,Antimalarials ,Young Adult ,Drug Therapy ,Parasite Groups ,parasitic diseases ,Parasitic Diseases ,Malaria, Vivax ,Humans ,Pharmacokinetics ,Disease Eradication ,MESH: Prevalence ,Aged ,Pharmacology ,MESH: Adolescent ,MESH: Humans ,MESH: Child, Preschool ,Infant, Newborn ,Biology and Life Sciences ,Infant ,MESH: Malaria, Vivax ,MESH: Adult ,South America ,Models, Theoretical ,Tropical Diseases ,MESH: Antimalarials ,MESH: Male ,Malaria ,Parasitology ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,People and places ,Plasmodium vivax ,MESH: Brazil ,Apicomplexa ,MESH: Female - Abstract
Background Despite recent intensification of control measures, Plasmodium vivax poses a major challenge for malaria elimination efforts. Liver-stage hypnozoite parasites that cause relapsing infections can be cleared with primaquine; however, poor treatment adherence undermines drug effectiveness. Tafenoquine, a new single-dose treatment, offers an alternative option for preventing relapses and reducing transmission. In 2018, over 237,000 cases of malaria were reported to the Brazilian health system, of which 91.5% were due to P. vivax. Methods and findings We evaluated the impact of introducing tafenoquine into case management practices on population-level transmission dynamics using a mathematical model of P. vivax transmission. The model was calibrated to reflect the transmission dynamics of P. vivax endemic settings in Brazil in 2018, informed by nationwide malaria case reporting data. Parameters for treatment pathways with chloroquine, primaquine, and tafenoquine with glucose-6-phosphate dehydrogenase deficiency (G6PDd) testing were informed by clinical trial data and the literature. We assumed 71.3% efficacy for primaquine and tafenoquine, a 66.7% adherence rate to the 7-day primaquine regimen, a mean 5.5% G6PDd prevalence, and 8.1% low metaboliser prevalence. The introduction of tafenoquine is predicted to improve effective hypnozoite clearance among P. vivax cases and reduce population-level transmission over time, with heterogeneous levels of impact across different transmission settings. According to the model, while achieving elimination in only few settings in Brazil, tafenoquine rollout in 2021 is estimated to improve the mean effective radical cure rate from 42% (95% uncertainty interval [UI] 41%–44%) to 62% (95% UI 54%–68%) among clinical cases, leading to a predicted 38% (95% UI 7%–99%) reduction in transmission and over 214,000 cumulative averted cases between 2021 and 2025. Higher impact is predicted in settings with low transmission, low pre-existing primaquine adherence, and a high proportion of cases in working-aged males. High-transmission settings with a high proportion of cases in children would benefit from a safe high-efficacy tafenoquine dose for children. Our methodological limitations include not accounting for the role of imported cases from outside the transmission setting, relying on reported clinical cases as a measurement of community-level transmission, and implementing treatment efficacy as a binary condition. Conclusions In our modelling study, we predicted that, provided there is concurrent rollout of G6PDd diagnostics, tafenoquine has the potential to reduce P. vivax transmission by improving effective radical cure through increased adherence and increased protection from new infections. While tafenoquine alone may not be sufficient for P. vivax elimination, its introduction will improve case management, prevent a substantial number of cases, and bring countries closer to achieving malaria elimination goals., In this modelling study, Narimane Nekkab and colleagues estimate that tafenoquine usage could result in a 38% reduction in P. vivax transmission over 2021-25., Author summary Why was this study done? Radical cure with tafenoquine plus chloroquine has been recently approved to treat P. vivax malaria; however, the impact of improving individual-level effective radical cure—by overcoming non-compliance with primaquine with this single-dose regimen—on population-level transmission is unknown. Depending on age, pregnancy and lactating status, and glucose-6-phosphate dehydrogenase (G6PD) phenotypic activity and drug metabolism, treatment eligibility and effective radical cure rates may vary across different populations with variable transmission. What did the researchers do and find? With mathematical modelling, we accounted for these complex dynamics to consider the non-linear dynamics of primaquine and tafenoquine treatment on the burden of P. vivax malaria across a range of settings and for various implementation strategies. To our knowledge, our work is the first to show how rolling out tafenoquine in populations will improve case management of P. vivax, reduce transmission, and prevent a substantial number of cases, even in settings with high rates of effective case management with primaquine. However, tafenoquine alone will not lead to P. vivax elimination. What do these findings mean? Accounting for the factors that lead to a variable degree of impact, our results can guide countries considering introducing tafenoquine with G6PD deficiency testing as part of tailored intervention strategies adapted to their local context. Overall, tafenoquine will have several public health benefits; however, it should be considered as an additional tool along with other interventions to reach elimination goals in the proposed time frame.
- Published
- 2021
- Full Text
- View/download PDF
42. Sperm proteins and cancer-testis antigens are released by the seminiferous tubules in mice and men
- Author
-
Peter G. Stanton, Lee B. Smith, Julien M. D. Legrand, Giuseppe Infusini, Frédéric Chalmel, Diane Rebourcet, Andrew I. Webb, Raouda Sgaier, Laura F. Dagley, Adrian Pilatz, Robin M. Hobbs, Wolfgang Weidner, Liza O'Donnell, Robert I McLachlan, Thorsten Diemer, Daniela Fietz, Peter J. O'Shaughnessy, Hudson Institute of Medical Research [Clayton], University of Newcastle [Australia] (UoN), The Walter and Eliza Hall Institute of Medical Research (WEHI), Justus-Liebig-Universität Gießen (JLU), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), University of Edinburgh, BB/J015105/1, Biotechnology and Biological Sciences Research Council, Deutsche Forschungsgemeinschaft, Chard-Hutchinson, Xavier, Justus-Liebig-Universität Gießen = Justus Liebig University (JLU), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and University of Newcastle [Callaghan, Australia] (UoN)
- Subjects
0301 basic medicine ,Male ,Proteome ,medicine.medical_treatment ,interstitial fluid ,[SDV]Life Sciences [q-bio] ,Biochemistry ,Mice ,0302 clinical medicine ,Cancer immunotherapy ,Neoplasms ,Research Articles ,Seminiferous Tubules ,Sertoli cell ,Spermatozoa ,cancer‐testis antigen ,3. Good health ,[SDV] Life Sciences [q-bio] ,medicine.anatomical_structure ,Cancer/testis antigens ,biomarker ,Immunotherapy ,Erratum ,cancer-testis antigen ,Biotechnology ,Research Article ,Biology ,testis ,sperm ,Andrology ,03 medical and health sciences ,Immune system ,Antigen ,Antigens, Neoplasm ,Genetics ,medicine ,Animals ,Humans ,Spermatogenesis ,Molecular Biology ,Blood-Testis Barrier ,Infertility, Male ,Sertoli Cells ,Cancer ,Proteins ,Extracellular Fluid ,medicine.disease ,030104 developmental biology ,Cancer biomarkers ,030217 neurology & neurosurgery - Abstract
International audience; Sperm develop from puberty in the seminiferous tubules, inside the blood-testis barrier to prevent their recognition as "non-self" by the immune system, and it is widely assumed that human sperm-specific proteins cannot access the circulatory or immune systems. Sperm-specific proteins aberrantly expressed in cancer, known as cancer-testis antigens (CTAs), are often pursued as cancer biomarkers and therapeutic targets based on the assumption they are neoantigens absent from the circulation in healthy men. Here, we identify a wide range of germ cell-derived and sperm-specific proteins, including multiple CTAs, that are selectively deposited by the Sertoli cells of the adult mouse and human seminiferous tubules into testicular interstitial fluid (TIF) that is "outside" the blood-testis barrier. From TIF, the proteins can access the circulatory- and immune systems. Disruption of spermatogenesis decreases the abundance of these proteins in mouse TIF, and a sperm-specific CTA is significantly decreased in TIF from infertile men, suggesting that exposure of certain CTAs to the immune system could depend on fertility status. The results provide a rationale for the development of blood-based tests useful in the management of male infertility and indicate CTA candidates for cancer immunotherapy and biomarker development that could show sex-specific and male-fertility-related responses.
- Published
- 2021
- Full Text
- View/download PDF
43. Heterogeneity in response to serological exposure markers of recent Plasmodium vivax infections in contrasting epidemiological contexts
- Author
-
Rosado, Jason, White, Michael T., Longley, Rhea J., Lacerda, Marcus, Monteiro, Wuelton, Brewster, Jessica, Sattabongkot, Jetsumon, Guzman-Guzman, Mitchel, Llanos-Cuentas, Alejandro, Vinetz, Joseph M., Gamboa, Dionicia, Mueller, Ivo, Malaria : parasites et hôtes - Malaria : parasites and hosts, Institut Pasteur [Paris], Santé publique : épidémiologie & sciences de l'information biomédicale (ED 393), Sorbonne Université (SU), The Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne, Instituto Leônidas e Maria Deane - Fiocruz Amazônia [Manaus, Brésil] (ILMD), Fundação Oswaldo Cruz (FIOCRUZ), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD), Mahidol University [Bangkok], Universidad Peruana Cayetano Heredia (UPCH), Yale University School of Medicine, This work was supported by National Health and Medical Research Council Australia grants 1092789, 1134989 and 1043345 to IM (https://www.nhmrc.gov.au/), the Global Health Innovative Technology Fund grant T2015-142 to IM (https://www.ghitfund.org/), National Institutes of Health-National Institute of Allergy and Infectious Diseases (NIH-NIAID) U19AI089681 to JMV (https://www.niaid.nih.gov). This work has been supported by FIND with funding from the Australian and British governments. The Brazilian team was partly funded by Fundação de Amparo à Pesquisa do Estado do Amazonas-FAPEAM (PAPAC 005/2019 and Pró-Estado). JR is supported by the Pasteur - Paris University (PPU) International PhD Program. RJL received the Page Betheras Award from WEHI to provide funding for technical support for this project during parental leave. RJL is supported by a NHMRC Early Career Investigator Fellowship (1173210). ML and WM are fellows of the Brazilian National Council for Scientific and Technological Development. MGG is supported by Training Grant 5D43TW007120 (https://www.fic.nih.gov)., Institut Pasteur [Paris] (IP), Fundação Oswaldo Cruz / Oswaldo Cruz Foundation (FIOCRUZ), and Yale School of Medicine [New Haven, Connecticut] (YSM)
- Subjects
Plasmodium ,Physiology ,RC955-962 ,serology ,immunogenicity ,Pathology and Laboratory Medicine ,Biochemistry ,Geographical locations ,Cohort Studies ,immunoglobulin G ,Medical Conditions ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Immune Physiology ,Arctic medicine. Tropical medicine ,Peru ,Medicine and Health Sciences ,Prevalence ,Longitudinal Studies ,Immune Response ,receiver operating characteristic ,Immune System Proteins ,seroprevalence ,Plasmodium vivax malaria ,Thailand ,Serology ,risk factor ,[SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology ,Antibody response ,pregnancy ,Public aspects of medicine ,RA1-1270 ,purl.org/pe-repo/ocde/ford#3.03.06 [https] ,Brazil ,Research Article ,Asia ,Immunology ,prevalence ,Plasmodium falciparum ,dispersity ,antibody titer ,Article ,Antibodies ,Parasite Groups ,parasitic diseases ,Parasitic Diseases ,Malaria, Vivax ,Humans ,follow up ,Serologic Tests ,human ,quality control ,Antigens ,Ascaris lumbricoides ,CD4+ T lymphocyte ,questionnaire ,Biology and Life Sciences ,Proteins ,antibody response ,South America ,Tropical Diseases ,vaccination ,discriminant analysis ,major clinical study ,enzyme linked immunosorbent assay ,Malaria ,sensitivity and specificity ,Immunoglobulin G ,Antibody Formation ,Parasitology ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,People and places ,Plasmodium vivax ,Apicomplexa ,Biomarkers - Abstract
Background Antibody responses as serological markers of Plasmodium vivax infection have been shown to correlate with exposure, but little is known about the other factors that affect antibody responses in naturally infected people from endemic settings. To address this question, we studied IgG responses to novel serological exposure markers (SEMs) of P. vivax in three settings with different transmission intensity. Methodology We validated a panel of 34 SEMs in a Peruvian cohort with up to three years’ longitudinal follow-up using a multiplex platform and compared results to data from cohorts in Thailand and Brazil. Linear regression models were used to characterize the association between antibody responses and age, the number of detected blood-stage infections during follow-up, and time since previous infection. Receiver Operating Characteristic (ROC) analysis was used to test the performance of SEMs to identify P. vivax infections in the previous 9 months. Principal findings Antibody titers were associated with age, the number of blood-stage infections, and time since previous P. vivax infection in all three study sites. The association between antibody titers and time since previous P. vivax infection was stronger in the low transmission settings of Thailand and Brazil compared to the higher transmission setting in Peru. Of the SEMs tested, antibody responses to RBP2b had the highest performance for classifying recent exposure in all sites, with area under the ROC curve (AUC) = 0.83 in Thailand, AUC = 0.79 in Brazil, and AUC = 0.68 in Peru. Conclusions In low transmission settings, P. vivax SEMs can accurately identify individuals with recent blood-stage infections. In higher transmission settings, the accuracy of this approach diminishes substantially. We recommend using P. vivax SEMs in low transmission settings pursuing malaria elimination, but they are likely to be less effective in high transmission settings focused on malaria control., Author summary Plasmodium vivax still poses a threat in many countries due to its ability to cause recurrent infections. Key to achieving the goal of malaria elimination is the ability to quickly detect and treat carriers of relapsing parasites. Failing to identify this transmission reservoir will hinder progress towards malaria elimination. Recently, novel serological markers of recent exposure to P. vivax (SEM) have been developed and validated in low transmission settings. It is still poorly understood what factors affect the antibody response to these markers when evaluated in contrasting endemic contexts. To determine the factors that influence the antibody response to SEM, we compared the antibody levels in three sites with different transmission intensity: Thailand (low), Brazil (moderate) and Peru (high). In this study, we found that transmission intensity plays a key role in the acquisition of the antibody repertoire to P. vivax. In highly endemic sites, it is likely that immunological memory resulting from a constant and sustained exposure will impact the performance of SEMs to detect individuals with recent exposure to P. vivax. In summary, SEMs that perform well in low transmission sites do not perform as well in high transmission regions.
- Published
- 2021
- Full Text
- View/download PDF
44. Chromosomes distribute randomly to, but not within, human neutrophil nuclear lobes
- Author
-
Michael J. Mlodzianoski, Carolyn A. de Graaf, Leonard C. Harrison, Christine R. Keenan, Naiara G. Bediaga, Hannah D. Coughlan, Thomas Boudier, Kelly L. Rogers, Timothy M. Johanson, Gaetano Naselli, Rhys S. Allan, Erin C. Lucas, Douglas J. Hilton, Gordon K. Smyth, Qike Wang, The Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne, Institut de Biologie Paris Seine (IBPS), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Gestionnaire, Hal Sorbonne Université, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
0301 basic medicine ,organizational aspects of cell biology ,Human neutrophil ,[SDV]Life Sciences [q-bio] ,Cell ,02 engineering and technology ,Biology ,Article ,Chromosome conformation capture ,immunology ,03 medical and health sciences ,optical imaging ,0302 clinical medicine ,medicine ,lcsh:Science ,030304 developmental biology ,0303 health sciences ,Multidisciplinary ,Chromosome Organization ,Chromosome ,Radial distribution ,021001 nanoscience & nanotechnology ,Imaging analysis ,Cell biology ,chromosome organization ,[SDV] Life Sciences [q-bio] ,030104 developmental biology ,medicine.anatomical_structure ,Polymorphonuclear cells ,Distribution pattern ,lcsh:Q ,0210 nano-technology ,030217 neurology & neurosurgery - Abstract
Summary The proximity pattern and radial distribution of chromosome territories within spherical nuclei are random and non-random, respectively. Whether this distribution pattern is conserved in the partitioned or lobed nuclei of polymorphonuclear cells is unclear. Here we use chromosome paint technology to examine the chromosome territories of all 46 chromosomes in hundreds of single human neutrophils – an abundant and famously polymorphonuclear immune cell. By comparing the distribution of chromosomes to randomly shuffled controls and validating with orthogonal chromosome conformation capture technology, we show for the first time that human chromosomes randomly distribute to neutrophil nuclear lobes, while maintaining a non-random radial distribution within these lobes. Furthermore, we demonstrate that chromosome length correlates with three-dimensional volume not only in neutrophils but other human immune cells. This work demonstrates that chromosomes are largely passive passengers during the neutrophil lobing process but are able to subsequently maintain their macro-level organization within lobes., Graphical abstract, Highlights • Human chromosomes randomly distribute to neutrophil nuclear lobes • However, they sustain a non-random radial distribution within these lobes • Chromosome length correlates with volume in neutrophils and other human immune cells • Gene-regulatory transchromosomal interactions are unlikely in human neutrophils, Immunology; optical imaging; chromosome organization; organizational aspects of cell biology
- Published
- 2021
- Full Text
- View/download PDF
45. Identification of the asymptomatic Plasmodium falciparum and Plasmodium vivax gametocyte reservoir under different transmission intensities
- Author
-
Thomas Obadia, Jetsumon Sattabongkot, Ingrid Felger, Wang Nguitragool, Andrea Kuehn, Wuelton Marcelo Monteiro, Ivo Mueller, Anne Cristine Gomes de Almeida, Lyndes Wini, Andreea Waltmann, Andrew Waleluma Darcy, Quique Bassat, Marcus V. G. Lacerda, Cristian Koepfli, Eline Kattenberg, Leanne J. Robinson, Patricia Rarau, Maria Ome-Kaius, James W. Kazura, The Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne, University of Notre Dame [Indiana] (UND), Mahidol University [Bangkok], Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD), Universidade do Estado do Amazonas (UEA), Universitat de Barcelona (UB), Papua New Guinea Institute for Medical Research (PNGIMR), Hub Bioinformatique et Biostatistique - Bioinformatics and Biostatistics HUB, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Malaria : parasites et hôtes - Malaria : parasites and hosts, Institut Pasteur [Paris], Case Western Reserve University [Cleveland], Ministry of Health and Medical Services [Solomon Islands], Centro de Investigação em Saúde de Manhiça [Maputo, Mozambique] (CISM), Institució Catalana de Recerca i Estudis Avançats (ICREA), Hospital Sant Joan de Déu [Barcelona], CIBER de Epidemiología y Salud Pública (CIBERESP), Swiss Tropical and Public Health Institute [Basel], This work was funded by the TransEPI Consortium/Bill and Melinda Gates Foundation (www.gatesfoundation.org, IM, OPP1034577), the Australian National Health and Medical Research Council (www.nhmrc.gov.au, IM, 1021544, 1092789), and NIH (www.nih.gov, JK, 1U19AI089686, IM, 1U19AI129392). This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS. CK was supported by a fellowship from the Swiss National Science Foundation (#P2BSP3_151880). LJR was supported by an NHMRC Early Career Fellowship #1016443 (www.nhmrc.gov.au). IM is supported by a NHMRC Senior Research Fellowship (www.nhmrc.gov.au). ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya (https://cerca.cat/en/). CISM is supported by the Government of Mozambique and the Spanish Agency for International Development (AECID, www.aecid.es)., Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), and Institut Pasteur [Paris] (IP)
- Subjects
Male ,Plasmodium ,Primaquine ,RC955-962 ,Gametocytes ,Geographical locations ,law.invention ,0302 clinical medicine ,Medical Conditions ,Dihydroartemisinin/piperaquine ,law ,Animal Cells ,Arctic medicine. Tropical medicine ,Medicine and Health Sciences ,Malaria, Falciparum ,Child ,Protozoans ,0303 health sciences ,Malarial Parasites ,Eukaryota ,Thailand ,3. Good health ,Infectious Diseases ,Transmission (mechanics) ,Child, Preschool ,Female ,Cellular Types ,Public aspects of medicine ,RA1-1270 ,Brazil ,medicine.drug ,Research Article ,Asia ,Adolescent ,030231 tropical medicine ,Oceania ,Plasmodium falciparum ,Biology ,03 medical and health sciences ,Papua New Guinea ,Young Adult ,Parasite Groups ,Solomon Islands ,parasitic diseases ,medicine ,Gametocyte ,Parasitic Diseases ,Malaria, Vivax ,Humans ,030304 developmental biology ,Public Health, Environmental and Occupational Health ,Organisms ,Biology and Life Sciences ,Infant ,Cell Biology ,South America ,biology.organism_classification ,medicine.disease ,Tropical Diseases ,Virology ,Parasitic Protozoans ,Malaria ,Germ Cells ,Cross-Sectional Studies ,Parasitology ,Asymptomatic Diseases ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,People and places ,Plasmodium vivax ,Apicomplexa - Abstract
Background Understanding epidemiological variables affecting gametocyte carriage and density is essential to design interventions that most effectively reduce malaria human-to-mosquito transmission. Methodology/Principal findings Plasmodium falciparum and P. vivax parasites and gametocytes were quantified by qPCR and RT-qPCR assays using the same methodologies in 5 cross-sectional surveys involving 16,493 individuals in Brazil, Thailand, Papua New Guinea, and Solomon Islands. The proportion of infections with detectable gametocytes per survey ranged from 44–94% for P. falciparum and from 23–72% for P. vivax. Blood-stage parasite density was the most important predictor of the probability to detect gametocytes. In moderate transmission settings (prevalence by qPCR>5%), parasite density decreased with age and the majority of gametocyte carriers were children. In low transmission settings (prevalence65% of gametocyte carriers were adults. Per survey, 37–100% of all individuals positive for gametocytes by RT-qPCR were positive by light microscopy for asexual stages or gametocytes (overall: P. falciparum 178/348, P. vivax 235/398). Conclusions/Significance Interventions to reduce human-to-mosquito malaria transmission in moderate-high endemicity settings will have the greatest impact when children are targeted. In contrast, all age groups need to be included in control activities in low endemicity settings to achieve elimination. Detection of infections by light microscopy is a valuable tool to identify asymptomatic blood stage infections that likely contribute most to ongoing transmission at the time of sampling., Author summary Plasmodium vivax and Plasmodium falciparum cause the vast majority of all human malaria cases. Across all transmission settings, a large proportion of infections of the two species remain asymptomatic. These infections are not diagnosed and treated by control programs focusing on clinical cases. They can carry gametocytes, the sexual stage of the parasite that establishes infections in mosquitos, thus asymptomatic infections contribute to transmission. In order to determine who is likely to contribute to transmission, gametocyte densities were measured by sensitive molecular methods in afebrile individuals in four countries. The proportion of infections with gametocytes varied greatly among surveys, and was higher in regions that had experienced low transmission for extended periods of time. In moderate-high transmission settings, gametocyte densities were particularly high in children below six years, highlighting the importance that interventions to reduce transmission include this age group. The majority of gametocyte carriers was positive by light microscopy. The comprehensive data on gametocyte carriage presented here lays the foundation for the development of more effective screen and treat activities to reduce malaria transmission.
- Published
- 2021
- Full Text
- View/download PDF
46. Investigating differences in village-level heterogeneity of malaria infection and household risk factors in Papua New Guinea
- Author
-
John B. Keven, Jason Rosado, Moses Laman, Cristian Koepfli, Ingrid Felger, Michelle Katusele, Lina Lorry, Daniela Rodriguez-Rodriguez, Natalie E. Hofmann, Manuel W Hetzel, Freya J. I. Fowkes, Elma Nate, Leanne J. Robinson, Alma Auwan, Mary Salib, Ivo Mueller, Maria Ome-Kaius, James W. Kazura, Stephan Karl, Desmond Gul, Archie C. A. Clements, Burnet Institute [Melbourne, Victoria], Swiss Tropical and Public Health Institute [Basel], University of Basel (Unibas), Papua New Guinea Institute of Medical Research (PNG-IMR), Michigan State University System, Biologie des Interactions Hôte-Parasite - Biology of Host-Parasite Interactions, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Sorbonne Université (SU), University of Notre Dame [Indiana] (UND), The Walter and Eliza Hall Institute of Medical Research (WEHI), Case Western Reserve University [Cleveland], James Cook University (JCU), Curtin University [Perth], Planning and Transport Research Centre (PATREC), Telethon KIDS Institute, The University of Western Australia (UWA), University of Melbourne, Monash University [Melbourne], This work was funded by WHO/Tropical Disease Research Program grant (WCCPRD4426109 2016/639607), NIH NIAID International Centres of Excellence in Malaria Research South West Pacific (U19 AI089686) and Asia Pacific (U19 AI129392-01) and NHMRC Australian Centre of Research Excellence for Malaria Elimination (ACREME GNT1134989). D.G. is supported by an Australian Government Research Training Program (RTP) Scholarship. M.K. is the recipient of a Wellcome Trust International Masters Fellowship. I.M. (GNT11155075), S.K. (GNT1141441) and L.J.R. (GNT1161627) are supported by NHMRC Fellowships., and Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Male ,Epidemiology ,Plasmodium ovale ,law.invention ,0302 clinical medicine ,law ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Prevalence ,030212 general & internal medicine ,Malaria, Falciparum ,Toilet Facilities ,2. Zero hunger ,Family Characteristics ,Multidisciplinary ,Mosquito Nets ,Coinfection ,New guinea ,3. Good health ,Spatial heterogeneity ,Geography ,Transmission (mechanics) ,Medicine ,Female ,medicine.medical_specialty ,Science ,030231 tropical medicine ,Article ,03 medical and health sciences ,Papua New Guinea ,Age Distribution ,Malaria elimination ,Environmental health ,parasitic diseases ,medicine ,Malaria, Vivax ,Humans ,Ecosystem ,Disease Reservoirs ,Construction Materials ,Drinking Water ,Odds ratio ,15. Life on land ,medicine.disease ,Health Surveys ,Malaria ,Cross-Sectional Studies ,Social Class ,Risk factors ,Vector (epidemiology) ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie - Abstract
Malaria risk is highly heterogeneous. Understanding village and household-level spatial heterogeneity of malaria risk can support a transition to spatially targeted interventions for malaria elimination. This analysis uses data from cross-sectional prevalence surveys conducted in 2014 and 2016 in two villages (Megiar and Mirap) in Papua New Guinea. Generalised additive modelling was used to characterise spatial heterogeneity of malaria risk and investigate the contribution of individual, household and environmental-level risk factors. Following a period of declining malaria prevalence, the prevalence of P. falciparum increased from 11.4 to 19.1% in Megiar and 12.3 to 28.3% in Mirap between 2014 and 2016, with focal hotspots observed in these villages in 2014 and expanding in 2016. Prevalence of P. vivax was similar in both years (20.6% and 18.3% in Megiar, 22.1% and 23.4% in Mirap) and spatial risk heterogeneity was less apparent compared to P. falciparum. Within-village hotspots varied by Plasmodium species across time and between villages. In Megiar, the adjusted odds ratio (AOR) of infection could be partially explained by household factors that increase risk of vector exposure, such as collecting outdoor surface water as a main source of water. In Mirap, increased AOR overlapped with proximity to densely vegetated areas of the village. The identification of household and environmental factors associated with increased spatial risk may serve as useful indicators of transmission hotspots and inform the development of tailored approaches for malaria control.
- Published
- 2021
- Full Text
- View/download PDF
47. Intestinal-derived ILCs migrating in lymph increase IFNγ production in response to Salmonella Typhimurium infection
- Author
-
Daniel M. Wall, Gabrielle T Belz, John J. Cole, Vuk Cerovic, Edward S Lee, Gérard Eberl, Natalie Papazian, Michio Tomura, Verena Kästele, David R. Withers, Carl S. Goodyear, Tom Cupedo, Simon Milling, Rose A. Maciewicz, Johannes U Mayer, Hematology, HUGOT, Bérengère, Institute of Infection, Immunity and Inflammation [Glasgow, UK], University of Glasgow, Albert Einstein College of Medicine [New York], Erasmus University Medical Center [Rotterdam] (Erasmus MC), The Walter and Eliza Hall Institute of Medical Research (WEHI), Rheinisch-Westfälische Technische Hochschule Aachen University (RWTH), Osaka Ohtani University [Osaka, Japan], Microenvironnement et Immunité - Microenvironment and Immunity, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Birmingham [Birmingham], V.K. was supported by the Versus Arthritis Rheumatoid Arthritis Pathogenesis Centre for Excellence (RACE) (grant number 20298). J.M. was supported by the Wellcome Trust 'Molecular Functions in Disease' Doctoral Training Programme. J.J.C. was supported by the GLAZgo Discovery Centre. V.C. was supported by a project grant from the Medical Research Council (MR/K021095/1)., RWTH Aachen University, and Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
0301 basic medicine ,Salmonella ,[SDV.IMM] Life Sciences [q-bio]/Immunology ,Immunology ,Innate lymphoid cell ,Cytokine expression ,C-C chemokine receptor type 7 ,Inflammation ,Biology ,medicine.disease_cause ,3. Good health ,body regions ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Immunity ,medicine ,Immunology and Allergy ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Lymph ,Transcriptional analysis ,medicine.symptom ,skin and connective tissue diseases ,030215 immunology - Abstract
Mucosal immunology 14(3), 717-727 (2021). doi:10.1038/s41385-020-00366-3, Published by Nature Publishing Group, New York, NY
- Published
- 2021
- Full Text
- View/download PDF
48. Discovery of a Family of Mixed Lineage Kinase Domain-like Proteins in Plants and Their Role in Innate Immune Signaling
- Author
-
Viera Kovacova, Lisa K. Mahdi, Leïla Brulé Kopp, Menghang Huang, Florence Jacob, Xiaoxiao Zhang, Jane E. Parker, Isabel M. L. Saur, Kay Hofmann, Paul Schulze-Lefert, Ryohei Thomas Nakano, Takaki Maekawa, Dmitry Lapin, James M. Murphy, Jijie Chai, Max Planck Institute for Plant Breeding Research (MPIPZ), Beijing Advanced Innovation Center for Structural Biology, Tsinghua-Peking Joint Center for Life Sciences, Tsinghua University [Beijing] (THU)-Tsinghua University [Beijing] (THU), Cluster of Excellence on Plant Sciences (CEPLAS), Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf]-Max Planck Institute for Plant Breeding Research (MPIPZ)-Universität zu Köln = University of Cologne, Institut des Sciences des Plantes de Paris-Saclay (IPS2 (UMR_9213 / UMR_1403)), Université d'Évry-Val-d'Essonne (UEVE)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, The Walter and Eliza Hall Institute of Medical Research (WEHI), Institute for Genetics, German Research Foundation (DFG)SFB-1403-414786233University of Cologne Centre of Excellence in Plant Sciences National Natural Science Foundation of China (NSFC)31421001National Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC)110575411729291124735IRIISS 9000587Victorian State Government Operational Infrastructure Support scheme Alexander von Humboldt Foundation, Universität zu Köln-Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf]-Max Planck Institute for Plant Breeding Research (MPIPZ), and Université d'Évry-Val-d'Essonne (UEVE)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
- Subjects
Protein Conformation ,Arabidopsis ,Apoptosis ,Arabidopsis-thaliana ,0302 clinical medicine ,Arabidopsis thaliana ,Plant Immunity ,Pattern-recognition Receptors ,Receptor ,Disease Resistance ,Plant Proteins ,0303 health sciences ,Gabi-kat ,Cell Death ,Pattern recognition receptor ,Membrane ,Cell biology ,Necroptosis ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Specificity ,Tir Domains ,Genome, Plant ,Intracellular ,Signal Transduction ,Protein family ,NLR Proteins ,Biology ,Microbiology ,Necrosis ,03 medical and health sciences ,Immune system ,Protein Domains ,Downstream ,Virology ,Animals ,Amino Acid Sequence ,ADP-ribosyl Cyclase ,030304 developmental biology ,Innate immune system ,Programmed Cell-death ,Disease Resistance Genes ,Arabidopsis Proteins ,Cryoelectron Microscopy ,biology.organism_classification ,Mutation ,Parasitology ,Protein Multimerization ,Protein Kinases ,030217 neurology & neurosurgery - Abstract
International audience; HeLo domain-containing mixed lineage kinase domain-like protein (MLKL), a pseudokinase, mediates necroptotic cell death in animals. Here, we report the discovery of a conserved protein family across seed plants that structurally resembles vertebrate MLKL. The Arabidopsis genome encodes three MLKLs (AtMLKLs) with overlapping functions in disease resistance mediated by Toll-interleukin 1-receptor domain intracellular immune receptors (TNLs). The HeLo domain of AtMLKLs confers cell death activity but is dispensable for immunity. Cryo-EM structures reveal a tetrameric configuration, in which the HeLo domain is buried, suggestive of an auto-repressed complex. The mobility of AtMLKL1 along microtubules is reduced by chitin, a fungal immunity-triggering molecule. An AtMLKL1 phosphomimetic variant exhibiting reduced mobility enhances immunity. Coupled with the predicted presence of HeLo domains in plant helper NLRs, our data reveal the importance of HeLo domain proteins for TNL-dependent immunity and argue for a cell death-independent immune mechanism mediated by MLKLs.
- Published
- 2020
- Full Text
- View/download PDF
49. Immunodynamics of explanted human tumors for immuno‐oncology
- Author
-
Dubuisson, Agathe, Fahrner, Jean Eudes, Goubet, Anne Gaëlle, Terrisse, Safae A., Voisin, Nicolas, Bayard, Charles, Lofek, Sébastien, Drubay, Damien, Bredel, Delphine, Mouraud, Séverine, Susini, Sandrine, Cogdill, Alexandria P., Rebuffet, Lucas, Ballot, Elise, Jacquelot, Nicolas, Thomas de Montpreville, Vincent, Casiraghi, Odile, Radulescu, Camélia, Ferlicot, Sophie, Figueroa, David J., Yadavilli, Sapna, Waight, Jeremy D., Ballas, Marc S., Hoos, Axel X., Condamine, Thomas, Parier, Bastien, Gaudillat, Christophe, Routy, Bertrand, Ghiringhelli, François, Derosa, Lisa, Breuskin, Ingrid, Rouanne, Mathieu, André, Fabrice, Lebacle, Cédric, Baumert, Hervé, Wislez, Marie, Fadel, Élie, Cremer, Isabelle, Albiges, Laurence, Geoerger, Birgit, Scoazec, Jean Yves, Loriot, Yohann, Kroemer, Guido, Marabelle, Aurélien, Bonvalet, Mélodie, Zitvogel, Laurence, Immunologie des tumeurs et immunothérapie (UMR 1015), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Gustave Roussy (IGR)-Université Paris-Sud - Paris 11 (UP11), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Service de biostatistique et d'épidémiologie (SBE), Direction de la recherche clinique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), The University of Texas M.D. Anderson Cancer Center [Houston], Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, The Walter and Eliza Hall Institute of Medical Research (WEHI), Département de biologie et pathologie médicales [Gustave Roussy], Institut Gustave Roussy (IGR), Centre hospitalier Saint-Joseph [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CR CHUM), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM)-Université de Montréal (UdeM), Département de médecine oncologique [Gustave Roussy], Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Hôpital Foch [Suresnes], Direction de la recherche [Gustave Roussy], AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), Vectorologie et thérapeutiques anti-cancéreuses [Villejuif] (UMR 8203), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Centre National de la Recherche Scientifique (CNRS), Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Karolinska University Hospital [Stockholm], Chancellerie des Universités de Paris Agence Nationale de la Recherche, ANR Seerave Foundation Association pour la Recherche sur le Cancer, ARC ANR‐16‐RHUS‐0008 Ligue Contre le Cancer European Commission, EC Fondation pour la Recherche Médicale, FRM Institut National Du Cancer, INCa Institut Universitaire de France, IUF European Research Council, ERC Fondation Leducq RP170067 Association pour la Recherche sur le Cancer, ARC, LZ and GK were supported by the Ligue contre le Cancer (équipe labelisée), Agence Nationale de la Recherche (ANR) francogermanique ANR‐19‐CE15‐0029, ANR Projects blancs, ANR under the frame of E‐Rare‐2, the ERA‐Net for Research on Rare Diseases, Association pour la recherche sur le cancer (ARC), Bristol‐Myers Squibb Company (International Immuno‐Oncology Network), Cancéropôle Ile‐de‐France, Chancellerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM), a donation by Elior, the European Commission (ArtForce), the European Research Council (ERC), Fondation Carrefour, Institut National du Cancer (INCa), Inserm (HTE), Institut Universitaire de France, LeDucq Foundation, the LabEx Immuno‐Oncology, the RHU Torino Lumière (ANR‐16‐RHUS‐0008), H2020 ONCOBIOME, the Seerave Foundation, the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE), FHU CARE, Dassault, and Badinter Philantropia, and the Paris Alliance of Cancer Research Institutes (PACRI). AC is supported by the CPRIT Research Training Program (RP170067). JEF was supported by Transgene and AGG was supported by FRM. AM has been or is currently an investigator in clinical trials sponsored by BMS, MSD, GSK/Tesaro, Janssen, Roche/Genentech, Pfizer, Astra Zeneca (AZ), Amgen. AM has been or is currently a member of Clinical Trial Scientific Steering Committee for AZ and GSK. AM has been or is currently a member of the scientific advisory board of the following companies: Merck Serono, Novartis, BMS, Symphogen, Amgen, Tesaro/GSK, Pfizer, Astra Zeneca/Medimmune, Servier, Sanofi. AM has provided Scientific & Medical Consulting to the following companies: Roche, Sanofi. AM is a member of the Data Safety and Monitoring Board for the following trial NCT02423863 (TLR3 agonist, Oncovir). AM has received research funding and or drug supply for pre‐Clinical and clinical research projects from: BMS, Boehringer Ingelheim, Idera, MSD, Fondation MSD Avenir, SIRIC (INCa‐DGOS‐Inserm_12551)., ANR-16-RHUS-0008,LUMIERE,LUMIERE(2016), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPC)
- Subjects
Medicine (General) ,[SDV]Life Sciences [q-bio] ,Immunology ,QH426-470 ,Medical Oncology ,immune checkpoint inhibitors ,R5-920 ,immunomonitoring ,Report ,precision oncology ,Neoplasms ,Genetics ,“in sitro” assay ,Tumor Microenvironment ,cancer ,Humans ,Immunotherapy ,Prospective Studies ,Reports - Abstract
Decision making in immuno‐oncology is pivotal to adapt therapy to the tumor microenvironment (TME) of the patient among the numerous options of monoclonal antibodies or small molecules. Predicting the best combinatorial regimen remains an unmet medical need. Here, we report a multiplex functional and dynamic immuno‐assay based on the capacity of the TME to respond to ex vivo stimulation with twelve immunomodulators including immune checkpoint inhibitors (ICI) in 43 human primary tumors. This "in sitro" (in situ/in vitro) assay has the potential to predict unresponsiveness to anti‐PD‐1 mAbs, and to detect the most appropriate and personalized combinatorial regimen. Prospective clinical trials are awaited to validate this in sitro assay., To predict cancer resistance to PD‐1 blockade and design suitable combinations of immunomodulators, a 60‐h functional in sitro assay was set up in 43 tumors that allowed calculation of the “Immune Reactivity Score (IRS)” based on 17 TCR‐dependent‐ cytokines/chemokines.
- Published
- 2020
- Full Text
- View/download PDF
50. Forest malaria in Cambodia: the occupational and spatial clustering of Plasmodium vivax and Plasmodium falciparum infection risk in a cross-sectional survey in Mondulkiri province, Cambodia
- Author
-
Nimol Khim, Michael T. White, Leanne J. Robinson, Benoit Witkowski, Saorin Kim, Amélie Vantaux, Mirco Sandfort, Soazic Gardais, Anais Pepey, Dysoley Lek, Ivo Mueller, Thomas Obadia, Malaria : parasites et hôtes - Malaria : parasites and hosts, Institut Pasteur [Paris] (IP), Malaria Molecular Epidemiology (MMEU), Institut Pasteur du Cambodge, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Hub Bioinformatique et Biostatistique - Bioinformatics and Biostatistics HUB, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), National Center for Parasitology, Entomology and Malaria Control [Phnom Penh, Cambodia] (CNM), National Institute of Public Health [Phnom Penh, Cambodge], The Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne, Burnet Institute [Melbourne, Victoria], This study is part of the International Centers of Excellence for Malaria Research programme 'Understanding, tracking and eliminating malaria transmission in the Asia–Pacific Region', funded by the National Institutes of Health, MD, US (grant 1U19AI129392-01) and received additional funding by NHMRC (Australia, GNT1092789). IM is supported by an NHMRC Principal Research Fellowship (GNT1155075). LJR is supported by an NHMRC Career Development Fellowship (GNT1161627). MS is part of the PhD programme of the doctoral school ED393 Pierre Louis de santé publique and supported by the Sorbonne Université (contract n°2695/2017). AP is supported by the Pasteur Institute International Network PhD fellowship programme 'Calmette & Yersin'., Institut Pasteur [Paris], Malaria Molecular Epidemiology, and Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Male ,Cross-sectional study ,Plasmodium vivax ,Vivax ,0302 clinical medicine ,Risk Factors ,Prevalence ,Cluster Analysis ,Spatial ,Malaria, Falciparum ,Child ,Asymptomatic Infections ,2. Zero hunger ,0303 health sciences ,biology ,Risk of infection ,Middle Aged ,3. Good health ,Occupational Diseases ,Infectious Diseases ,Child, Preschool ,Female ,medicine.symptom ,Cambodia ,Adult ,medicine.medical_specialty ,lcsh:Arctic medicine. Tropical medicine ,Adolescent ,lcsh:RC955-962 ,Plasmodium falciparum ,030231 tropical medicine ,Asymptomatic ,lcsh:Infectious and parasitic diseases ,Young Adult ,03 medical and health sciences ,parasitic diseases ,Malaria, Vivax ,medicine ,Humans ,Greater Mekong Subregion ,lcsh:RC109-216 ,Forest ,Aged ,030304 developmental biology ,Spatial Analysis ,business.industry ,Research ,Public health ,Infant ,15. Life on land ,medicine.disease ,biology.organism_classification ,Cross-Sectional Studies ,Tropical medicine ,Hotspots ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Parasitology ,Occupational risk ,business ,Malaria ,Demography - Abstract
Background After a marked reduction in malaria burden in Cambodia over the last decades, case numbers increased again in 2017–2018. In light of the national goal of malaria elimination by 2025, remaining pockets of high risk need to be well defined and strategies well-tailored to identify and target the persisting burden cost-effectively. This study presents species-specific prevalence estimates and risk stratification for a remote area in Cambodia. Methods A cross-sectional survey was conducted in 17 villages in the high-incidence province Mondulkiri in the dry season (December 2017 to April 2018). 4200 randomly selected participants (2–80 years old) were tested for Plasmodium infection by PCR. Risk of infection was associated with questionnaire-derived covariates and spatially stratified based on household GPS coordinates. Results The prevalence of PCR-detectable Plasmodium infection was 8.3% (349/4200) and was more than twice as high for Plasmodium vivax (6.4%, 268) than for Plasmodium falciparum (3.0%, 125, p P. vivax and 92.8% (116/125, p P. falciparum infections were neither accompanied by symptoms at the time of the interview nor detected by microscopy or RDT. Recent travels to forest sites (aOR 2.17, p p Plasmodium infection were observed, ranging from 0.6% outside the forest to 40.4% inside. Residing in villages at the forest fringe or inside the forest compared to outside was associated with risk of infection (aOR 2.14 and 12.47, p Conclusions Persisting pockets of high malaria risk were detected in forested areas and in sub-populations engaging in forest-related activities. High levels of asymptomatic infections suggest the need of better case detection plans and the predominance of P. vivax the implementation of radical cure. In villages inside the forest, within-village exposure was indicated in addition to risk due to forest activities. Village-level stratification of targeted interventions based on forest proximity could render the elimination efforts more cost-effective and successful.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.